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Abstract 
 
INVESTIGATION OF SUGAR MODIFIED PYRIMIDINE NUCLEOSIDES 
AS POTENTIAL INHIBITORS OF THYMIDINE (TP) AND URIDINE (UP) 
PHOSPHORYLASE 
 
Key words: uridine phosphorylase, thymidine phosphorylase, 
nucleoside, inhibitor, anticancer chemotherapy, substrate specifity 
 
The work deals with the investigation of novel potential inhibitors of 
recombinant thymidine and uridine phosphorylases from E. coli and Salmonella 
typhimurium. The main goals of this study are the determination of kinetic 
parameters for natural substrates (thymidine and uridine) for recombinant TP 
and UP, assessment of the role of phosphate anion in the enzymatic 
transformations and search for new inhibitors of TP and UP. Study of UP and 
TP substrate specifity and activity under the various reaction conditions is 
desired to obtain better view to their functions and to design novel structures of 
potencial inhibitors.  
The determination of the Michaelis constant KM and reaction rate Vmax  
was performed at the spectrophotometer Varian Cary-300 Bio. The 
representation of obtained kinetic data we used the Lineweawer-Burk plot. The 
next point of my work was the determination of the enzymatic activity and their 
substrate specifity for some pyrimidine analogues by HPLC analysis of reaction 
mixtures. Tested compounds 2´-O-methyluridine, 1-(ß-D-fructofuranosyl)uracil, 
2´-deoxy-2´-fluorouridine, 2´-amino-2´-deoxyuridine, 3´-amino-3´-deoxyuridine 
and 3´-amino-3´-deoxythymidine showed various abilities to be phosphorylated. 
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Abstrakt 
 
STUDIUM PYRIMIDINOVÝCH NUKLEOSIDŮ MODIFIKOVANÝCH NA 
CUKERNÉ ČÁSTI JAKO POTENCIÁLNÍCH INHIBITORŮ TYMIDIN (TP) A 
URIDIN (UP) FOSFORYLÁZY 
 
Klíčová slova: uridinfosforyláza, tymidinfosforyláza, nukleosid, inhibitor, 
protinádorová chemoterapie, substrátová specifita 
 
Práce se zabývá studiem nových potenciálních inhibitorů rekombinantní 
tymidinfosforylázy a uridinfosforylázy z bakterií E. coli a Salmonella 
typhimurium. Hlavním předmětem studia je určení kinetických parametrů 
přirozených substrátů (tymidinu a uridinu) pro rekombinantní TP a UP, určení 
role fosfátového aniontu v enzymatické reakci a a hledání nových inhibitorů TP 
a UP. Studium substrátové specifity a aktivity TP a UP za různých reakčních 
podmínek je důležité pro získání lepšího pohledu na jejich funkce a pro 
vytvoření nových struktur potenciálních inhibitorů. 
Stanovení Michaelisovy konstanty KM a limitní rychlosti Vmax bylo 
provedeno s využitím spektrofotometru Varian Cary-300 Bio. Pro grafické 
znázornění kinetických dat jsme využili Lineweaver-Burkův diagram. Dalším 
bodem mé práce bylo stanovení aktivity enzymů a jejich substrátové specifity 
pro některé pyrimidinové analogy pomocí HPLC analýzy reakčních směsí. 
Testované sloučeniny, 2´-O-metyluridin, 1-(ß-D-fruktofuranosyl)uracil, 2´-
deoxy-2´-fluorouridin, 2´-amino-2´-deoxyuridin, 3´-amino-3´-deoxyuridin a 3´-
amino-3´-deoxytymidin vykazovaly různě velkou schopnost fosforylace. 
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 Abbreviations 
 
 
2FUrd 2´-deoxy-2´-fluorouridine 
dAdo 2´-deoxyadenosine 
dCyd 2´-deoxycytidine 
dGuo 2´-deoxyguanosine 
D-dRib 2-deoxy-D-ribose 
D-dRib-1-P 2-deoxy-D-ribose-1-phosphate 
L-dRib 2-deoxy-L-ribose 
2Cl-Ade 2-chloroadenine 
5´-DFUR 5´-deoxy-5-fluorouridine 
KIN59 5´-O-tritylinosine 
BAU 5-benzylacyclouridine 
BU 5-benzyluracil 
TPI 
5-chloro-6-[1-(2-iminopyrrolidinyl)methyl]uracil 
hydrochloride 
BBBA 5-m-benzyloxybenzyl barbituric acid acyclonucleoside 
BBAU 5-m-benzyloxybenzylacyclouridine 
BBU 5-m-benzyloxybenzyluracil 
6A5BU 6-amino-5-bromouracil 
7DX 7-deazaxanthine 
TP65 9-(8-phosphonooctyl)-7-deazaxanthine 
ara-C 9-(β-D-arabinofuranosyl)cytosine 
ara-G 9-(β-D-arabinofuranosyl)guanine 
ara-U 9-(β-D-arabinofuranosyl)uracil 
Arg arginine 
CD cytidine deaminase 
FGF-2 fibroblast growth factor-2 
Glu glutamic acid 
Gln glutamine 
GA glutaraldehyde 
Gly glycine 
Guo guanosine 
His histidine 
Ile isoleucine 
Lys lysine 
MMP matrix metalloproteinase 
Met methionine 
SN1 nucleophilic substitution 1 
NRTIs nucleoside analogue reverse transcriptase inhibitors 
NP  nucleoside phosphorylase 
Phe phenylalanine 
PD-ECGF platelet-derived endothelial cell growth factor 
PNPBs PNP from Bacillus stearothermopylus 
Pro proline 
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PNP purine nucleoside phosphorylase 
RNA ribonucleic acid 
Ser serine 
Thr threonine 
TP thymidine phosphorylase 
Tyr tyrosine 
UP uridine phosphorylase 
Val valine 
VEGF vascular endothelial growth factor     
  10 
Introduction 
 
Analogues of natural nucleosides are very important compounds in the 
treatment of many viral diseases and also play a significant role in the 
anticancer and immunomodulating therapy. Thymidine and uridine 
phosphorylase are crucial enzymes involved in pyrimidine-salvage pathways. 
They catalyze the reversible phosphorolysis of thymidine to thymine and 2-
deoxy-D-ribose and uridine to uracil and ribose.  
 
Thymidine phosphorylase (TP) is highly overexpressed in many tumors, 
it has angiogenic activity, supports endothelial cell migration and protects cells 
from the apoptosis induced by hypoxia. The role in tumor development makes 
the TP as really important target in the treatment of cancer. Together with the 
finding of angiogenic activity of TP, the research focused on searching of new 
inhibitors.  
 
Uridine phosphorylase (UP) activity has been also shown to be apparent 
in various human solid tumors and connected with reducing the effectiveness 
of several chemotherapeutic pyrimidine nucleoside analogues, such as 
capecitabine or tegafur, prodrugs of 5-fluorouracil.  
 
The qualities of TP and UP outline interesting possibility of therapeutic 
intervention in tumor growth by specific inhibition of these two enzymes. We 
focused on determining of kinetic parameters and substrate specifity of UP and 
TP. Study of UP and TP substrate specifity and activity under the various 
reaction conditions is desired to obtain better view to their functions and to 
design novel structures of potencial inhibitors. With respect to the high 
similarity in nucleoside binding sites presented in human and bacterial 
enzymes, we used for our work recombinant TP from Escherichia coli and UP 
from Escherichia coli and from Salmonella typhimurium. 
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1  Rewiew of literature 
 
1.1 Thymidine phosphorylase 
 
Thymidine phosphorylase (TP) is an important enzyme involved in the 
pyrimidine nucleoside salvage pathway. Its main function is the reversible 
phosphorolysis of pyrimidine 2´deoxynucleosides to 2-deoxyribose-1-
phosphate and their respective pyrimidine basis. TP makes the transfer of the 
deoxyribose from one pyrimidine base to the next out. 
 
thymidine + phosphate 
  
 2-deoxyribose-1-phosphate + thymine 
 
It was presumed that, under phisiological conditions, TP always takes 
effect towards catabolism in contrast to the UP, which is able to act towards 
both catabolism and anabolism. In the catalytic mechanism, pyrimidine 
nucleosides are bounded in the high-energy conformation and the flow of 
electrons from the O5´ of the pentose ring weakens the glycosodic bond to free 
the pyrimidine.  
 
   
Fig. 1 Structures of thymine and thymidine 
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1.1.1 Occurrence in nature 
 
Thymidine phosphorylase is of widespread occurrence in 
microorganisms. [4] This enzyme has been purified from a variety of 
mammalian tissues, as well as several bacterial sources. [5] TP belongs to the 
Pyrimidine Nucleoside Phosphorylase family. In lower organisms there is only 
one enzyme PNP (Pyrimidine nucleoside phosphorylase) which uses both 
thymidine and uridine as substrates. In mammalian cells there are two 
enzymes – UP for uridine and TP for thymidine. It was shown that TP is more 
exacting than UP in discerning of ligands. [2] 
 
Besides the natural 2´-deoxynucleosides thymidine and 2´-deoxyuridine, 
TP recognises several nucleoside analogues that are being used clinically as 
antiviral and/or anti-tumour agents, such as 5-(E)-(2-bromovinyl)-2´-
deoxyuridine (BVDU), 5-trifluoromethyl-2´-deoxyuridine (TFT, F3dThd), 5-iodo-
2´-deoxyuridine (IDU), or 5-fluoro-2´-deoxyuridine (FdUrd) and many others. [2]   
 
1.1.2 Mechanism of action of TP 
 
The catalytic mechanism of action of thymidine phosphorylase was 
elucidated by Mendieta et al. [6] Their hypothesis that His85 plays an important 
role in the catalytic mechanism was confirmed. They showed that His85 can be 
involved in the transfer of the proton from the phosphate to the O2 thymine and 
also that the enol form of the free base is the most likely intermediate product. 
The next feature is the ability to stabilize the transition state in process of the 
catalysis. Furthermore it was observed that His85 is totally conserved in the 
PNP family. 
 
For determination of mechanism of action they used targeted molecular 
dynamics simulations and quantum mechanical calculations by comparing the 
enzymatic reactions of two substrates, thymidine and 2-thiothymidine.  
 
It was found out that the mechanism of phosphorolysis proceeds as two-
step reaction like SN1.  
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The first step: the O2 of molecule of thymidine interacts with a proton of 
histidine residue, concretely with a proton from the protonated imidazole ring. 
This process makes the pyrimidine base a better leaving group. An intermediate 
oxycarbocation in the sugar is induced by weakened glycosidic bond. The first 
step usually runs slower, it is rate limiting.  
 
The second step is a fast reaction between this carbocation and the 
phosphate dianion acting as a nucleophile that gives rise to 2-deoxribose-1-
phosphate and the enol form of thymine. In this mechanism, positively charged 
His85 donates a proton to the thymidine whereas the phosphate dianion is used 
as the nucleophile for the stabilization of the transition state of the enzyme in 
the second step. The enol form as the product of the reaction then 
spontaneously tautomerize to the more stable keto form. [6] 
 
1.1.3 Structural aspects and binding sites of TP 
 
A molecule of thymidine phosphorylase consists of two identical 
subunits, its molecular mass ranges from 90 kDa in Escherichia coli to 110 kDa 
in mammals. Members of TP family show a noticeable sequence homology. For 
example, human TP is in 39% homologous with E. coli TP.  
 
Each subunit of TP molecule includes a small α domain that contains 
thymidine binding site and of a large α/β domain where the phosphate binding 
site is situated. The phosphate binding site is stabilized by a salt bridge with 
Lys84 and hydrogen bonds made up by rezidues of this α/β domain lining this 
pocket. The thymine/thymidine binding site in the smaller α domain creates 
interactions with O2, O4 and N3 atoms of thymidine with Arg171, Ser186 and 
Lys190. In the human TP dimer interface, the α helices play important role. This 
interface is formed by α3 helices from each monomer and α1 helix from one 
monomer connected to α8 and α9 helices from the other monomer. 
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Fig. 2 The residues forming the interactions in the pyrimidine and phosphate binding site of 
thymidine phosphorylase (pictures available at http://arginine.chem.cornell.edu/Structures/) 
 
There exist some structural differences between human TP,  TP from 
Escherichia coli and PNP from Bacillus stearothermophilus (PNPBs). The main 
differences are in the α/β domain where human TP has an additional helix so 
called α15, an extra turn in α16, and a more prolonged C-terminal end. The 
small antiparallel β sheet in human TP and in PNPBs is not present in TP from 
E. coli. There exist two forms of active sites: open and closed, which are 
separated by low-energy barrier. To generate a catalytically active site a domain 
closure is necessary.  
 
The best accurate structural determination of the active site of the human 
TP is important for further investigation and prediction of novel structures and 
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for the searching of the effect of known inhibitory active compounds. The 
comparison of the human TP, E. coli TP and PNPBs has shown that the overall 
structural similarity between human TP and E. coli TP is quite less than 
between the human TP and PNPBs, while the similarity between the separate 
domains fits well. [2], [27] 
 
 
Fig. 3 Crystal structure of human TP. (a)A picture showing the human TP dimer and the 
dimerization interface; the thymines present in the active sites are shown as sticks. 
(b)The diagram showing the overall fold of the human TP monomer [8] 
 
1.1.4 TP as PD-ECGF 
 
Previously thymidine phosphorylase was known as platelet-derived 
endothelial cell growth factor (PD-ECGF). In 1987, PD-ECGF was isolated from 
human platelets and later from placenta tissue. So that TP stimulates 
endothelial cell migration and angiogenesis.  
 
Angiogenesis and anticancer chemotherapy 
 
Angiogenesis is a complex process requiring cooperation between a 
planty of celullar factors involving the growth of new blood vessels. There are 
more than 20 angiogenic growth factors, e.g. vascular endothelial growth factor 
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(VEGF), angiopoietins, matrix metalloproteinase (MMP) or fibroblast growth 
factor-2 (FGF2).   
 
Before that the coincidence between TP and PD-ECGF was 
documented, it was found that TP levels are higher in plasm of pacients with 
any type of cancer than in healthy individuals and further it is overexpressed at 
a high level in tumors. Many solid tumours are dependent on density of blood 
vessels, that is why they produce increased levels of thymidine phosphorylase 
than non-neoplastic tissues. High concentrations of TP are found in tumours 
including carcinoma of stomach, colon, ovary and bladder, carcinoma of 
pancreas, renal carcinoma, oesophageal, breast and lung cancer. TP is also 
overexpressed in some chronic inflammatory diseases like human 
atherosclerosis, psoriasis and rheumatoid arthritis. For example, Moghadam et 
al. [28] have found that TP expression is tightly connected to origin of 
malignancies in breast tumors and assays in vitro showed that the growth of 
carcinoma cells is not supported by TP, whereas the growth in vivo is 
accelerated. [2] [28]  
 
The activity of TP is connected with hypoxia and easier breakout of 
angiogenesis in malignant and hyperproliferative states. In addition, TP inhibits 
tumour cell apoptosis. The formation of an intratumoural network of blood 
vessels is required to provide the growing tumour with oxygen and nutrients. In 
addition, tumor neovascularization prevents tumours from undergoing necrosis 
and apoptosis and facilitates the escape of tumour cells into the circulation and 
subsequent metastasis to distant organs. [4] [27] [28] 
 
The mechanism by which thymidine phosphorylase causes the 
development of blood vessels is not absolutely clear. But TP enzymatic activity 
is essential for stimulation of angiogenesis. 2-deoxy-D-ribose as a product of TP 
enzymatic action was found to produce radicals of oxygen. They induce the 
secretion of oxidative stress-response angiogenic factors, e.g. VEGF, MMP and 
interleukin-8. In addition, 2-deoxy-D-ribose is able to activate specific integrins. 
This reaction connects endothelial cell migration induced by TP to intracellular 
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signal transduction pathways. That is why the TP enzyme activity which is 
necessary for angiogenesis should be inhibit by TP inhibitors. [8] 
 
 
Fig. 4 Not only cancer cells but also inflammatory cells that infiltrate the tumour and 
extracelullar matrix can be a source of angiogenesis factors. Picture was downloaded 
from www.med.unibs.it/~airc/cancer.html 
 
Anti-angiogenic therapy, against activated endothelial cells, offers 
several advantages over therapy directed against tumor cells. Endothelial cells 
are a genetically stable homogenous target, and spontaneous mutations rarely 
occur. Anti-angiogenic therapy is directed at activated endothelial cells, its 
target should be easily accessible by systemic administration. The activated 
endothelium presents a more specific target because of the expression of 
specific markers, than the tumor cells, and inhibition of a small number of tumor 
vessels may affect the growth of many tumor cells. 
 
1.1.5 The identity of TP and gliostatin 
 
Thymidine phosphorylase is also known as gliostatin, initially isolated 
from human neurofibroma as glial growth inhibitory factor. Gliostatin plays an 
important role on development and regeneration of the central nervous system. 
This name, gliostatin, is mainly used in connection with rheumatoid arthritis and 
cortical neurons. It is integrated probably in the development of the blood-brain 
barrier [2] 
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1.2 Uridine phosphorylase 
 
Uridine phosphorylase is a key enzyme involved in the utilization of 
pyrimidines. It catalyzes the reversible phosphorolysis of ribosides and 2´-
deoxyribosides of uracil and their analogues to the relevant nucleobases and 
ribose-1-phosphate or 2´-deoxyribose-1-phosphate. [9] 
 
Pyrimidine-(2´-deoxy)ribose + phosphate 
 
  Pyrimidine + (2´-deoxy)ribose-1-Phosphate 
 
   
Fig. 5 Structures of uracil and uridine 
 
Uridine phosphorylase is widespread enzyme which has been identified 
in procaryotes, yeast and higher organisms. The sequence of amino acids is 
highly conserved among several bacterial, mouse and human enzymes. [10] 
 
Inhibiting UP in human liver raises the blood uridine concentration and in 
this way is produced a protective effect (so called uridine rescue) against the 
toxicity of the chemotherapeutic agent 5-fluorouracil without decrease of its 
antitumor activity. In this reason research focused on developing of UP 
inhibitors is in progress. 
UP 
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1.2.1 Structure of UP and binding sites from Escherichia coli 
 
1.2.1.1 Structure of UP 
 
The molecule of UP from Escherichia coli is a  hexamer 100 Å in 
diameter and 40 Å thick. Homohexamer is disc-shaped with a long channel 
opened at each end, which runs through the center of the hexamer. The 
hexameric quarternary structure of the enzyme is in principle trimer of dimers, 
where two active sites occur in each dimer and are located at the interface of 
two monomers. [10]  
 
 
Fig. 6 The active form of the enzyme E. coli UP is a hexamer of identical subunits with a 
molecular weight of 165 kDa. (http://arginine.chem.cornell.edu/Structures/EcUP.html) 
 
A monomer of E. coli UP 
 
A monomer consists of one large β-sheet flanked on one side by four α-
helices and on the other side by three α-helices and a shorter β-sheet. [9] The 
β-sheet centre of UP is bifurcated with α6-helix parting strands β6 and β9. Here 
α6-helix creates the base of a small β barrel. The central twisted β-sheet is 
lined with several α-helices with the longest C-terminal helix (α7), packing 
against two shorter helices, α1 and α4, with each helix paralel with its closest β 
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strand. At the opposite side of the central twisted β-sheet, α2-helix lies there in 
a similar way, while α3-helix packs against both α2 and α6-helices. [10] 
 
 
Fig. 7 A monomer unit of E. coli UP includes 253 amino acid residues. 
(http://arginine.chem.cornell.edu/Structures/EcUP.html) 
 
Structure of dimer and hexamer 
 
The subunit contacts of monomer of the UP dimer are created by quite 
big amount of residues. Except the Asp160 and His122 the central area of the 
monomer-monomer interface is constituted of hydrophobic interactions. In the 
neighbourhood of this central hydrophobic place, there is a group of polar 
residues that form the remaining monomer-monomer interactions. The loop 
made up of amino acids 163-185 in UP results in an increased interface area of 
monomer-monomer contact in contrast to the similar region of PNP. The 
majority of interactions between the UP dimers that creates the hexamer are 
formed through hydrophobic residues. The dimer-dimer interface consists of a 
central hydophobic area with interlocking ridges formed by the 128-134 regions 
of both dimers. The loop 163-185 is involved in polar dimer-dimer interactions. 
These residues creates interactions with the monomer of the neighbouring 
dimer. The side-chain of Arg178 situated at the entrance of the central channel 
of the hexamer makes up a hydrogen bonding with the Lys181 in the 
contiguous dimer. Other dimer-dimer interactions are made up by Arg175 and 
Glu186. [10] 
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1.2.1.2 E. coli UP active site 
 
The active site contains a highly conserved amino-acid residues. Each 
active site contains important parts which are given from near neighboring 
monomer. [9]   
 
The pyrimidine binding site 
 
The uracil binding pocket of an occupied UP active site forms a 
rectangular slot. Residues Thr95, Gly96, Tyr195, Glu196 and Phe162 form the 
surface of the active site. The neighbouring region of C5 of uracil is formed by 
Ile220 and Val221 and the edge consists of Pro229 and Phe7 from the 
adjacent monomer. These residues form a hydrophobic pocket at the 5 position 
of uracil. The key residue is Gln166, it is conserved in all UPases. The side-
chain of Gln166 makes up two hydrogen bonds to uracil, one of them forms the 
atom of nitrogen to O2 of uracil and the second bond is formed by the carbonyl 
oxygen atom to N3 of uracil. The carbonyl makes up the second hydrogen 
bond to a structural molecule of water, which itself forms a hydrogen bond to 
O4 of uracil. In the midst of the side-chains Arg223 and Phe162 there is placed 
the side-chain of Arg168 which forms hydrogen bonds to carbonyls of the main 
chain. The residues Gln166, Arg168 and Arg223 are conserved in the 
structures of E.coli UP and human UP. [10]    
 
The ribose binding site 
 
The ribose-binding site can accomodate either ribosyl or 2´-deoxyribosyl 
moiety. [9] This active site lies between the phosphate and uracil binding sites. 
The ribose is located in the area of active site by a network of hydrogen bonds, 
mainly by the side-chain His8 and Glu198. The ribose 5´ hydroxyl forms 
hydrogen bonds with His8 and a molecule of water presented in the active site 
too. Glu198 creates two hydrogen bonds to the 2´ and 3´ hydroxyl groups of 
the ribose moiety. The 3´ hydroxyl of ribose forms one hydrogen bond to O3 
atom of the phosphate ion. The next important interaction is made up of 2´ 
hydroxyl of ribose and Met197 and Arg91. Met197 is connected in forming of 
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the ribose binding pocket and the atom of sulphur of methionine may act in 
stabilising the C2´-C3´-C4´ area of ribose. The methionine residue is absolutely 
conserved in the whole NP-I family of enzymes. His8, Arg91, Glu198 and 
Met197 forming hydrogen bonds are presented in all UPases. [1], [10] 
 
The phosphate binding site 
 
Both subunits of the dimer are involved in binding of phosphate moiety of 
ribose-1-phosphate. This site is formed by three arginine residues, Arg30, 
Arg48 and Arg91. Each of them makes two hydrogen bonds with the atom of 
oxygen of phosphate. Hydrogen bonds are made up also by one side chain 
hydroxyl and  two nitrogen atoms of the main chain (the side-chain hydroxyl of 
Thr94 and the main-chain nitrogen atoms of Thr94 and Gly26). [10]   
 
Comparison of all known UPases showed, that phosphate-binding site is 
highly conserved except Arg48, which can be substituted by a lysine [9]. 
 
The phosphate binding site of UP and PNP showes hardly identical 
arrangement of residues because of the evolutionary relationship and 
conserved function of both enzymes [10], which was further testified by Burling 
et al. [11]    
 
1.2.2 Relationship of E.coli UP to human UP 
 
Sequence alignment between UP from E. coli and human UP reveals a 
21% identity and 35% similarity, however, almost all the active-site residues are 
absolutely conserved. Only Arg48, which acts in binding of phosphate is 
replaced by lysine in human UP. [9] Probably these two enzymes have similar 
quarternary structures. [1] 
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Fig. 8 The residues at the pyrimidine binding site and in the phosphate binding site of 
uridine phosphorylase 
(http://arginine.chem.cornell.edu/Structures/StructurePictures/ECUPAS1.jpg, 
http://arginine.chem.cornell.edu/Structures/StructurePictures/ECUPAS2.jpg). 
 
1.2.3 Similarity between E.coli UP and E. coli PNP 
 
Uridine phosphorylase from E. coli and pyrimidine nucleoside 
phosphorylase from E. coli display significant structural homology. They have 
hexameric quarternary structure, simillar size and their secondary structural 
elements show the same position. There is one main structural distinction 
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between theese two enzymes. The region of residues 165-181 in UP formes 
prolonged loop, but this region in PNP contains only three amino acids in 
position 163-165 and forms short loop. This region 163-185 contains Gln166 
and Arg168, the key residues in UP specifity. [10], [11] 
 
1.2.4 Mechanism of action of UP 
 
1.2.4.1 Conformational changes in the presence of substrate 
 
The active site undergoes some conformational changes after the 
binding of a molecule of substrate.  
 
A large part of molecule of uridine phosphorylase is changed in 
conformation after binding of substrate, concretely parts of β5, β6, β7 and β9 
sheets, than the N-terminal part of α7 helix and residues 224-230 called a flap. 
This flap undergoes the longest movement and brings Glu227 closer to the 
specifity region where Glu227 creates two pairs of hydrogen bonds. One pair of 
bonds is formed to th eside-chain of Arg168, while the second pair of hydrogen 
bonds is formed to the main-chain atoms of nitrogen of Tyr169 and Asp170. 
The flap-movement also encloses the hydrophobic Pro229 in Ile220 and Phe7. 
There exist several other changes in the active site, the movement of Met234 
or the rotation of C-terminal end of  α7. [10] 
 
Closed phosphate binding sites display significantly stronger electron 
density for Arg30, which is stabilised by the pair of hydrogen bonds formed to 
phosphate oxygens and by enclosure of the mobile region. In the presence of 
phosphate, Arg91 is able to change its conformation and to make up two 
hydrogen bonds to phosphate oxygen and to Glu196. A molecule of water 
forms hydrogen bonds to Glu196 and Arg91. [10]  
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1.2.4.2 Influence of potassium ions 
 
In the presence of a potassium ion at the monomer-monomer interface 
there is induced some local change, which causes a stabilisation of dimer of 
UP and forming its closed conformation. Six atoms of oxygen, three from each 
monomer, play a role as ligands. The ligands are the side-chain of Glu49, the 
main-chain carbonyl of Ile69 and the side-chain of Ser73. These ligands are 
arranged in a octahedral geometry. [10] 
 
The Glu49 side-chain swings into the binding pocket for potassium when 
the potassium ion is bound and therefore the monomers are able to come 
closer. If the potassium ion is lacking, the Glu49 jumps away. This motion of 
Glu49 side-chain has impact on the structure of UP dimer. This side-chain goes 
between the two monomers and it serves as a wedge to push the monomers 
apart. It causes the movement of Pro28 and Arg48 apart. [10]  
 
1.2.4.3 Substrate specifity for natural nucleosides 
 
Uridine phosphorylase is specific for utilization of pyrimidines and the 
inability to metabolize purines is a result of the smaller space of the base 
binding pocket because of a presence of sequence 163-185. [10] UP from E. 
coli is more specific than the other UPases, it utilizes almost exclusively uridine 
and its analogues. [9] 
 
Uridine vs. thymidine: The higher affinity of UP for ribosides over 2´-
deoxyribosides is probably due to the three hydrogen bonds made up by the 
OH2´ of the ribosides and residues Arg91, Glu198 and Met197. Therefore the 
absence of OH2´ group in the molecule of thymidine, together with the small 
distortions of the uracil binding pocket required for accomodation of the methyl 
group at the 5 position of the molecule of the base may explain the lower 
affinity of uridine phosphorylase for thymidine in contrast to uridine. 
  
Uridine vs. cytidine: The molecule of cytidine could not be utilized 
because the nitrogen atom at the 3 position is at physiological pH deprotonated 
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and therefore is impossible to create a hydrogen bond to the carbonyl group of 
Gln166. The 4 position of cytidine contains the amino group, this group shows 
a δ+ charge on the amino protons, the charge-charge repulsion is generated 
between this charge and the positive charge of the guanidinium group from 
Arg168. This repulsion reduces the binding affinity of cytidine. In the structure 
of uridine there is a negative charge at the 4 position. It means that the 
conserved residue Arg168 plays an important role in the substrate specifity of 
uridine phosphorylase by an electrostatic effect. [10] 
 
1.2.4.4 Catalysis mediated by UP 
 
Because of the similarity of structures between uridine phosphorylase 
and the NP-I family and the high degree of conservation in binding sites, the 
mechanism of catalysis proceeds in a high probability in the similar way in both 
enzymes, UP and PNP. At first, the nucleoside reach a shape into high-energy 
+anti conformation. Then this process leads to the positioning of the ribose O4´ 
between O5´ of the ribose and O1 of the phosphate. This placement creates an 
electron push and evocates an electron flow from O4´. During the catalysis it 
was observed that nucleophiles of phopshate and pyrimidine stay embedded 
and the anomeric carbon atom proceeds along the energetically useful 
trajectory towards the phosphate nucleophile (the anomeric carbon atom is C1´ 
of the ribose). Protonation of uracil makes the base a better leaving group. A 
water molecule creates two hydrogen bonds to the O4 of uridine and to the 
Arg223. In contrast to previously mentioned PNP, in UP, there is unclear where 
a proton originates if water is not involvedas a proton donor. And the next 
important mark along the reaction is the geometric arrangement of the side-
chains of His8 and Glu80 in the binding of ribose. The side-chain of Glu80 
forms hydrogen bonds to His8, Leu9 and Tyr163. His8 is kept in the correct 
position to create one hydrogen bond to the OH5´ of ribose. It is possible that 
this arrangement deprotonate the 5´-hydroxyl group of the molecule of ribose to 
form O5´ more electron-rich and makes the creation of of transition state 
formation possible. [10] 
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A comparison of human and E.coli UP shows that sequence identity 
exists between these enzymes for all residues that form hydrogen bonds or 
π-stacks to substrate. 
Gly26, Arg30, Arg48, Arg91, Thr94 in phosphate binding pocket. 
His8, Glu198, Met197 in ribose binding pocket. 
Phe162, Gln166, Arg168, Arg223 in uracil binding pocket.  
 
Therefore the complexed E.coli UP sructures provide a good model for 
the human homologue and a reasonable template for structure-based drug 
design initiatives of inhibitors. [10] 
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1.3 TP and UP as biocatalysts for the synthesis of nucleosides 
 
The application of enzymes or the whole cells as biocatalysts causes an 
improvement of synthesis of nucleoside analogues. These methods of 
preparation of nucleosides are effective, the  biocatalysts are more stable under 
the conditions of reaction and the whole process becomes more cost-effective.  
[12] 
1.3.1 Methods of preparation 
 
Significant progress in the preparation of nucleoside analogues was 
obtained by combination of chemical and biochemical methods. [12] The 
chemical synthesis of nucleoside analogues is multistep process and very 
laborious and complicated. On the other hand, the synthesis using enzymes for 
the enzymatic transglycosylation of purine basis presents the convenient 
alternative to chemical methods. Biochemical reactions are joined with using 
cytidine deaminase, uridine phosphorylase, thymidine phosphorylase and 
purine nucleoside phosphorylase and the other enzymes. [13]  
1.3.2 Biocatalysts 
 
It is possible to use either purified enzymes or whole bacterial cells as 
biocatalysts for these reactions. Vladimir N. Barai et al. [13], [12] have selected 
three strains of Escherichia coli cells expressing significant enzyme activities.  
 
E. coli BM-11 – shows broad specifity in relation to nucleoside 
analogues and was employed for the synthesis of a variety of base- and sugar-
modified nucleosides. This strain shows high UP, TP, PNP activities and 
moreover the high CD activity. It was discovered that the utilization of E. coli 
BM-11 cells cross-linked by glutaraldehyde (GA) shows some experimental 
advantages over unmodified cells. The cross-linked cells by glutaraldehyde are 
shown to be more effective over the alginate gel-entrapped cells, are more 
stable and have better catalytic activity in synthesis of nucleosides than the 
unmodified cells (cross-linked cells retain operational stability and catalytic 
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activity up to 65°). Furthermore they could be used repeatedly in reactions 
performed at 60-65°. [12]  
E. coli BMT-1D/1A – is possible to use for the synthesis of thymidine or 
for example 2-chloro-2´-deoxyadenosine (cladribine) (using dGuo, dAdo or 
dCyd as donors of 2-deoxyribofuranose moiety),  
E. coli BMT-4D/1A – the new strain of E. coli BMT-4D/1A was found to 
be very effective for the syntheses of purine nucleoside analogues by usage 
pyrimidine nucleosides as donators of the carbohydrates for 
transglycosylations. [13] This strain is more efficient than the others for the 
synthesis of 2´-deoxy-2´-fluoroguanosine and 2,6-diamino-9-(3-deoxy-β-D-
erythro-pentofuranosyl)purine. [12] 
 
1.3.3 Synthesis of modified nucleosides 
 
These procedures became effective for the preparation of modified 
nucleosides with usage of sugar-modified pyrimidine nucleosides as donors of 
the pentofuranoses.  
 
One example of preparation of nucleoside analogues using bacterial 
enzymes as biocatalysts is described below: 
 
1.3.3.1 Synthesis of cladribine 
 
The chemical synthesis of cladribine is quite laborious. It leads to the 
origination of two stereoisomers and is necessary to treat the mixture to obtain 
molecule of cladribine.  
 
The first enzymatic approach for the synthesis of cladribine ( 2-chloro-2´-
deoxyadenosine) is based on the straight transfer of the 2-deoxyribofuranose 
from thymidine to 2-chloroadenine (2Cl-Ade). This reaction is catalyzed by 
trans-N-deoxyribosylase. [12] 
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The second approach seems to be really more advantageous with the 
action of PNP from E. coli BMT-4D/1A cells than the previous approach. 
Cladribine was synthesized by two coupled reversible reaction. The first step of 
the enzymatic transdeoxyribosylation is the phosphorolysis of 2´-
deoxyguanosine (dGuo) in the presence of phosphate ions. This step results in 
the origination of guanine and the important 2-deoxy-α-D-ribofuranose-1-O-
phosphate. The second step rests in the connection between 2Cl-Ade and 2-
deoxy-α-D-ribofuranose-1-O-phosphate with the following release of phosphate 
and forming of the molecule of cladribine (Fig. 17(d)). [12] 
 
Reactions used for syntheses of cladribine are examples of the way how 
to synthesized novel nucleoside analogues through the action of bacterial 
enzymes. Because of that the study of UP and TP substrate specifity and 
synthesis of their novel substrates  are necessary for further development of 
purine analogues, hardly synthesized by chemical methods.  
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1.4 Nucleoside analogues of medicinal importance  
 
1.4.1 Pharmacologically used pyrimidine nucleoside analogues 
 
Several nucleoside analogues are used as antiviral, anticancer and 
immunomodulating drugs. These compounds are derived from the natural 
pyrimidine nucleosides as thymidine (more precisely called deoxythymidine), 
uridine and cytidine. Novel applications of nucleosides are still being found for 
the clinic usage. 
 
 In most cases, nucleosides serves as prodrugs or bioprecursors that 
have to be activated to their pharmacologically active metabolites by enzymes 
presented in human tissues. Some of the nucleoside analogues do not require 
the activation and they are active in themselves. In some cases, these 
analogues are joined at the substrate-binding site of the enzyme but does not 
serve as a substrate. Therefore they can be used as an competitive inhibitors 
in connection with natural substrates. It happens, in a few cases, that the 
nucleoside does not bind at the substrate-binding site, but is bounded in 
another part of the molecule of enzyme. This analogues behave as 
noncompetitive inhibitors and the binding site is called allosteric binding site. 
[15]  
 
1.4.1.1 Anticancer chemotherapeutics 
 
5-Fluorouracil (5-FU) - An orally-administered chemotherapeutic agent 
capecitabine is the prodrug, which is converted through the 5´-deoxy-5-
fluorouridine to 5-FU (Fig. 9). The enzymes UP and TP were shown to be 
important enzymes for this activation. 5-fluorouracil, a fluorinated pyrimidine, is 
a key anti-colorectal cancer drug and it is used in the treatment of breast, head 
and neck tumors. 5-FU affects the synthesis and repair of DNA and RNA 
processing in cancer cells. Its antitumor activity is ascribed to thymidylate 
synthase inhibition. The host toxicity of 5-FU is related to RNA dysfunction 
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caused by incorporation of this molecule. [16] The typical administration with 
leucovorin (folinic acid) caused the potentiation of the effect of 5-FU. 
 
  
 
Fig. 9 Structure of capecitabine and 5-fluorouracil 
  
5´-deoxy-5-fluorouridine is an important intermediate in the capecitabine 
metabolism. Capecitabine is metabolized by PNP, UP and TP. Wan L. et al., 
[16] reported the importance of tumor necrosis factor-alpha (TNF-α) for the 
antiproliferative activity of 5´-deoxy-5-fluorouridine (5´-DFUR). They resulted 
from the knowledge that the expression of the UP gene was elevated in cancer 
cells by an incidence of cytokines. Thanks to TNF-α, the sensitivity of cells to 5´-
deoxy-5-fluorouridine and its incorporation into RNA and DNA is increased. The 
antitumor activity of 5-FU targetes the thymidylate synthase inhibition and DNA 
destruction. That means the more TNF-α exposition is presented the more UP 
expression is induced and the more 5´-deoxy-5-fluorouridine could be utilized 
and could increase its cytotoxicity. 
 
Cytarabine (Ara-C) is used for treatment of meningeal leukemia and 
with the combination with other drugs treats acute myeloid and lymphoblastic 
leukemia and chronic myelogenous leukemia.  Ara-C is converted to Ara-C 
triphosphate, which is an important factor for a blockage of DNA synthesis. [17] 
 
Azacytidine (5-azacytidine) reversibly inhibits DNA methyltransferase, 
this blocking of DNA methylation causes the activation of tumor suppresor 
genes. Mainly used in treatment of myelodysplastic syndrome. 
 
Floxuridine (FdUrd, 5-fluoro-2´-deoxyuridine) inhibits thymidylate 
synthetase leading to the disturbance in DNA synthesis and cytotoxicity. This 
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agent is an analog of 5-fluorouracil and is of use in treatment of colorectal 
cancer. 
 
 
Fig. 10 Structure of floxuridine 
 
Gemcitabine (difluorodeoxycytidine) is able to inhibit ribonucleotide 
reductase via its intermediate metabolites, thereby causing the decreased DNA 
synthesis. Lung, pancreatic, breast, bladder and oesophageal cancer is 
sensitive on the treatment. 
 
 
Fig. 11 Gemcitabine 
 
1.4.1.2 Antivirals 
 
Idoxuridine (IDU, 5-iodo-2´-deoxyuridine) serves as antiviral agent 
against Herpesviruses. Idoxuridine breaks the DNA synthesis. 
 
Trifluridine (F3dThd, 5-tirfluoromethyl-2´-deoxyuridine) like previous 
nucleoside analogues inhibits competetively the incorporation of natural 
nucleosides into DNA molecule. It is effective against Herpes simplex viruses. 
[18] 
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Fig. 12 Idoxuridine and trifluridine. 
 
1.4.1.3 Antiretrovirals 
 
Nucleoside antiretrovirals (NRTIs) are made up of synthetic 
dideoxynucleosides. The major part of NRTIs is made up by pyrimidine 
nucleoside analogues. The mechanism of action is mediated by the inhibition of 
reverse transcriptase. The nucleoside have to be activated to the triphosphate 
metabolite.  In the clinical practise, there is used a variety of combination of 
NRTIs, except stavudine, which is not possible to administered together with 
zidovudine because of the arisen inhibition of zidovudine. [17], [18]  
 
NRTI Synonym 
Zidovudine  azidothymidine 
Zalcitabine  dideoxycytidine 
Lamivudine  deoxythiacytidine 
Stavudine  dideoxythymidine 
Emtricitabine  5-fluoro-dideoxythiacytidine 
 
Table 1 NRTIs, their commonly used names and synonyms. 
 
  
Fig. 13 Antiretrovirals based on the structure of pyrimidine nucleosides. This figure depicts 
structure of zidovudine, one representative of  NRTIs. 
 
  35 
1.4.2 Purine nucleoside analogues of medicinal importance 
 
In medicinal practice, there is used a number of purine nucleoside 
analogues derived from natural purine nucleosides (adenosine and guanosine). 
They are administered at the same way as pyrimidine nucleoside analogues as 
antivirals, antiretrovirals and anticancer chemotherapeutics.  
 
1.4.2.1 Antivirals 
 
Acyclovir (acycloguanosine, ACV) – competetively inhibits viral DNA 
polymerase. .This molecule is efficient against Herpes simplex, varicella-zoster 
and other viruses. 
 
Ganciclovir (nordeoxyguanosine, 2´NDG) – the mechanism of action 
is similar to the inhibition caused by acyclovir and is used for treatment of 
cytomegalovirus infections. 
 
 
Fig. 14 Antiviral agents acyclovir and ganciclovir. 
 
Vidarabine (adenine arabinoside, ARA-A) – is also inhibitor of DNA 
polymerase with efficacy against Herpes viruses. 
 
Ribavirin (RIBA) – is active against a variety of DNA and RNA viruses, 
for example hepatitis C virus.  
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Fig. 15 Ribavirin 
 
Entecavir – makes the reproduction of hepatitis B virus slower by 
interruption of DNA synthesis. [18] 
 
1.4.2.2 Antimetabolites 
 
Mercaptopurine (6-thiohypoxanthine, MP) – this analogue of 
hypoxanthine shows an antineoplastic and immunosuppresive activity, which is 
used, as thioguanine, for  the acute leukemia treatment. 
 
 
Fig. 16 Mercaptopurine 
 
Thioguanine (TG) -  inhibits DNA synthesis. 
 
Fludarabine (2-F-ARA) – is fluorinated analogue of vidarabine affecting 
the wrong DNA synthesis and inhibiting the tumor cell growth. 
 
Nelarabine – its metabolite Ara-G causes the tumor cell apoptosis. 
 
Clofarabine – is suitable for acute lymphoblastic leukemia treatment. 
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Cladribine (2-chlorodeoxyadenosine, 2CDA) – caused the wrong 
synthesis of DNA, depletion of nicotineamide adenine nucleotide and 
adenosine triphosphate and is administered to patients diseased a hairy cell 
leukemia. [18] 
 
 
Fig. 17 Fludarabine (a), nelarabine (b), clofarabine (c) and cladribine (d). 
 
1.4.2.3 Antiretrovirals 
 
Didanosine (dideoxyinosine, ddI) – acts as a viral reverse 
transcriptase inhibitor. [18] 
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1.5 Development of inhibitors 
 
In many cancers, there is higher level of nucleoside phosphorylases 
presented than in normal cells. This high level is connected with elevated 
enzymic activity and with the cytokinin action. Effective inhibitors of these 
nucleoside phosphorylases are of good promise as potencial anticancer or 
antiviral drugs. New structures could be acceptable for direct treatment of 
cancer or for improvement of the effectivity of other anticancer drugs. [14] 
 
1.5.1 Thymidine phosphorylase inhibitors 
 
Inhibitors of thymidine phosphorylase are of good promise for enlargment 
the effectivity of anticancer chemotherapy by their potential to inhibit 
neovascularization of tumor tissues. 
 
1.5.1.1 First generation of inhibitors 
 
The first effective TP inhibitors, 6-aminothymine, 6-amino-5-chlorouracil 
and 6-amino-5-bromouracil, were obtained in the sixties. By virtue of their 
structure is obvious that free positions 2, 3 and 4 of the molecule of uracil are 
important for the realization of binding to TP active site and that the presence 
of Cl, Br or CH3 substituents in the 5 position causes the increase of inhibitory 
abilities, which could be explained by the presence of hydrophobic space in TP 
active site suitable for binding of these substituents. Similar hydrophobic space 
is probably shown up in the position 6 also, by that reason, a lot of TP inhibitors 
are 6-amino or 6-methylenamino compounds. [2] 
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Fig. 18 Prime inhibitors of TP: 6AT (6-aminothymine), 6A5CU (6-amino-5-chlorouracil) and 
6A5BU (6-amino-5-bromouracil) 
 
1.5.1.2 6-Aminouracil as basic structure 
 
The next group of TP inhibitors originated by the addition of the second 
ring on the pyrimidines like 7-deazaxanthine (7DX) and 7-(2-aminoethyl)-
deazaxanthine. 7DX was described as the first  purine analogue able to inhibit 
the function of TP. These compounds make up very stable bonds to substrate-
binding site of the enzyme. C7 and C8 positions of the pyrrole ring of 7DX have 
the same function as the methyl group of the thymine molecule at the C5 
position. Very potent inhibitory activity against human TP was documented for 
6-(2-aminoethylamino)-5-chlorouracil (AEAC) and 5-chloro-6-(1-
imidazolylmethyl)uracil (CIMU) (inhibitor of both TP and UP), where is shown 
the value of basic chain at 6 position. [2], [21] 
 
 
Fig. 19 TP inhibitor 7-deazaxanthine (7DX) 
 
1.5.1.3 Pyridinium-substituted derivatives of uracil and thymine 
 
These bicyclic pyridinium-substituted derivatives of uracil and thymine 
were prepared as the potencial inhibitors of TP to enlarge the group of 
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inhibitors based on modified uracil represented by 6-amino-5-bromouracil 
(6A5BU). Two groups of analogues were synthesized with substitution in C6 
and N1 position on the uracil or thymine ring.   
 
Preparation of C6-derivatives gave rise to three groups of uracil/thymine 
analogues (Fig. 20 (A)):  
 the direct fusion of pyridine to the uracil ring 
 from 6-(chloromethyl)uracil and neat pyridine or 2-amino or 3-
aminopyridine were prepared methylene bridged bicyclic 
compounds or the aminopyridinium compounds 
 thymine derivatives were prepared from 5,6-dimethylpyrimidine-
2,4-dione giving the methylene bridged pyridinium analogues. 
 
N1 thymine analogues (Fig. 20 (B)) forming the fourth group were 
synthesized of using methylpyridine or ethylpyridine.  
  
More than ten compounds were prepared in this way and were tested for 
the inhibitory activity to thymidine phosphorylase. 6-methylenepyridinium 
derivatives were marked as the most effective uracil-based inhibitors of TP. 
The most active compound was 1-[(5chloro-2,4-dihydroxypyrimidin-6-
yl)methyl]pyridinium chloride. Derivatives containing methylene bridge between 
their two heterocycles were the most potent inhibitors, because this methylene 
group caused increase of the molecular flexibility and facilitated the binding of 
molecule into the active site of TP. As was found, free N1 position is also very 
important for binding of enzyme, because N1-substituted derivatives displayed 
low inhibitory activity. C5-halogeno substitution of the uracil ring causes the 
increased acidity of the N1-group and in that way increased polarity of this 
group and stronger binding with the active site. [22]  
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Fig. 20 This picture shows the TP inhibitors, (A) represents general structure of C6-substituted 
uracil pyridinium derivatives, (B) represents general structure of N1-substituted derivatives. R
1 
presents substitution with halogenides or methylene, R
2
 subtituents are hydrogen or amino group.  
  
1.5.1.4 Inhibitors substituted with pyrrolidine or guanidine moiety 
 
According to the strucural determination of E. coli and Bacillus 
stearothermophylus TP active site closed conformation were designed 
following molecules. Efficient substitutions at 6 position gave rise to other 
modifications like 6-methyleneamino and N-methylguanidine uracil derivatives. 
Indeed, compounds containing 6-methylenepyrrolidine substituents, 5-chloro-
(6-methylenepyrrolidine)uracil and 5-bromo-(6-methylenepyrrolidine)uracil, 
show inhibitory activity, but their relatively high toxicity is disadvantage. 
Because of that N-methylguanidine and amidino derivatives were synthesized, 
for example 5-chloro-6-(1-N-methylguanidine)uracil hydrochloride or highly 
interesting 5-chloro-6-[1-(2-iminopyrrolidinyl)methyl]uracil hydrochloride (TPI). 
Based on the high inhibitory activity of TPI, N-(2,4-dioxo-1,2,3,4-tetrahydro-
thieno[3,2-d]pyrimidin-7-yl)guanidines were established, but their activity 
against TP was guite lower than TPI exhibited, which was caused by 
hydrophilic guanidine moiety. According to the E. coli TP open-cleft 
conformational state, other new alternative scaffolds of inhibitors based on 5-
substituted N-methylhydantoin or 5-substituted 2,4,6-pyrimidinetrione were 
obtained. The N-methylhydantoin moiety reacts nearby the phosphate-binding 
site and 2,4,6-pyrimidinetrione moiety racts in the thymine-binding site of the 
enzyme. [2]  
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Fig. 21 Inhibitors containing pyrrolidine or guanidine moiety. 5-chloro-6-[1-(2-
iminopyrrolidinyl)methyl]uracil hydrochloride (TPI),  5-halo-(6-methylenepyrrolidine)uracil 
(X=Cl, Br) (C), 5-chloro-6-(1-N-methylguanidine)uracil hydrochloride (D) and N-(2,4-dioxo-1,2,3,4-
tetrahydro-thieno[3,2-d]pyrimidin-7-yl)guanidine (E). 
 
1.5.1.5 Multisubstrate inhibitors 
 
These multisubstrate inhibitors interact not only at one binding site but at 
two binding sites at the same time. According to the open conformation of 
E. coli TP, these substances were developed. The active site in the open 
(inactive) conformation contains the thymine/thymidine and phosphate binding 
site, which are approximately 8-10 Å. Based on this distance, compounds 
involving pyrimidine base, 6-9 atoms long linking chain and the phosphonate 
group were synthesized to immobilize the enzyme in an inactive conformation. 
The most active compounds contain the 6A5BU or 7-deazaxanthine moiety. [2] 
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Fig. 22 Examples of multisubstrate inhibitors: 9-(8-phosphonooctyl)-7-deazaxanthine (TP65) and 1-
(8-phosphonooctyl)-6-amino-5-bromouracil (TP64). 
 
One of very potent compound is TP65 
(9-(8-phosphonooctyl)-7-deazaxanthine) which distinctively inhibited the blood 
vessel formation in enzymatic assays and is largely better inhibitor than its 
precursor 7DX. It is good to mention that TP65 was tested for cytotoxic activity 
against endothelial cell cultures and it was found that this compound is not 
toxic in the concentration necessary to inhibit blood vessels development. [21] 
 
1.5.1.6 Prodrugs of known inhibitors 
 
Because TP is expressed in various tumors in relatively high levels than 
in normal tissues, it is supposed to synthesized inhibitors of this enzyme acting 
only in tumors. It is matter of common knowledge that the environment in tumor 
tissues is characterized by hypoxia. The following prodrugs have the ability to 
be reduced to corresponding active compounds.  
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There are two approaches for the activation: 
 
 The nitroimidazolylmethyluracil prodrugs were designed according 
to the active site structure of E. coli TP and due to the supposition 
that the enzyme is able to distinguish between the nitro and the 
amino group. Very efficient inhibitors were 
5-halo-2-amino-imidazolylmethyluracils in the oposite to their 
nitroimidazolylmethyluracil prodrugs, which were many times less 
effective. 
 The next approach for the synthesis is based on the ability of the 
enzyme xanthine oxidase to utilize many compounds because of 
its broad substrate specifity. High levels of the enzyme are 
expressed in hypoxic tissues, which means in tumor tissues also. 
Prodrugs lacking the carbonyl group are oxidised by xanthine 
oxidase at the 2 and 4 positions of the nucleobase ring to create 
TP inhibitors like 6A5BU, 7DX or TPI. [2]  
 
 
Fig. 23 Prodrugs and their corresponding active molecules: 5-halo-2-nitroimidazolylmethyluracils 
(F), 5-halo-2-amino-imidazolylmethyluracils (G) and compounds (H), (I) and (J) which serve as 
substrates for xanthine oxidase. 
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1.5.1.7 Allosteric inhibitors of thymidine phosphorylase 
 
Allosteric inhibitors are ligands which cause the decrease of the affinity of 
the enzyme to substrate by binding to the allosteric active site, which is 
different and topographically distinct from the substrate binding site. These 
allosteric compounds do not need to keep the similar structure as the natural 
substrates and can serve for better understanding of enzymatic processes. 
N-phenylhomophtalimide and 5´-O-tritylinosine (KIN59) derivatives have been 
described. [2], [8], [15] 
 
5´-O-tritylated nucleoside derivatives 
 
The inhibitory activity was discovered for the KIN59 which contains 
nucleobase (hypoxanthine), ribose and a trityl moiety at the 5´-position of the 
ribose. This interesting compound does not compete neither with natural 
nucleoside nor with the phosphate at their binding sites, but it acts as 
noncompetitive inhibitor of TP. KIN59 showed that it is able to completely 
inhibits the neovascularization without being toxic.  
 
 
Fig. 24 Basic structure of 5´-O-tritylated deriatives KIN59 (5´-O-tritylinosine) 
 
The trityl moiety is necessary for causing the antiangiogenic activity. 
KIN59 became the prototype for synthesis of new compounds based on its 
structure (as was shown in Fig. 26), which could also show the inhibitory 
activity via the allosteric inhibition. The modifications in the molecule were 
carried on all parts, the base, sugar and trityl moieties. The insertion of the 
chlorine atom on the trityl group brought the increase of anti-TP activity (e.g. 
TP136). The next change at the molecule was methylation of the base, but this 
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modification did not bring the increase of inhibitory activity (TP140) as 
compared to KIN59. The methoxy-substitution on the trityl group led to 
instability of compounds and therefore they were not applicable (TP146, TP147 
and D7154) as well as derivatives prepared by replacement of hypoxanthine by 
the adenine or 6-methyladenine, which were instable also (TA-01 and TP141). 
The elevation of inhibitory activity against TP was achieved by replacement of 
hypoxanthine by thymine, while the change by uracil or 5-methylcytosine 
caused the rise of inhibitory activity on the same level as KIN59. After the 
removing of the base or changing the base by related hererocyclic substituent, 
the inhibitory activity disappeared, which means that the presence of 
heterocyclic base is necessary for the effectivity. Interestingly, the compound 
TP151 was found to be efficient inhibitor of TP-induced angiogenesis, although 
it does not inhibit the activity of TP.  
 
Further modifications were performed at KIN59 molecule by Casanova et 
al. [15]. The highly reactive N1 position of nucleobase was substituted by an 
alkyl, alkenyl or a benzyl group and as the optimal substituent was designated 
a methylcycloalkyl group with high inhibitory activity. Next, these N1-substituted 
derivatives underwent the cleavage of the purine ring to subsequent  
5-amino-4-(N-alkylcarbamoyl)imidazole ribosides (AICAR) (as was shown in 
Fig. 26). For the elucidation of the importance of sugar moiety to the inhibitory 
activity, 2´,3´-seconucleosides were synthesized by oxidative cleavage of the 
ribose (Fig. 25). With respect to the detection of their inactivity against TP it 
means that not only the purine base but also the sugar moiety is necessary for 
the interaction with TP allosteric binding site. [8], [15] 
 
 
Fig. 25 The KIN59 derivate 5´-O-trityl-2´,3´-secoinosine 
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Fig. 26 Several structures of 5´-O-tritylated nucleoside derivatives [8] 
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So that the trityl group is indispensable for the realization of anti-TP and 
antiangiogenic activity of these derivatives and the presence of this group is the 
main requirement for the allosteric binding probably at a lipophylic part of TP. 
The angiogenesis is stimulated by many other angiogenic factors, not only by 
TP, therefore the inhibition of blood vessel formation could be caused by 
interaction of 5´-O-tritylated derivatives with different angiogenic molecules. 
This possible interaction could be illustrated by the angiogenic activity of 
TP151, which do not inhibit TP. Therefore, this new group of inhibitors is 
important for their possible ability to interfere with another angiogenic factors 
than with TP. The next interesting point is that 5´-O-tritylated derivatives are 
able to cause destruction of already matured vessels at the area of drug 
administration. This destruction is not caused by a toxic effect of represented 
compounds, because the cytotoxicity in various assays was not observed. 
5´-O-tritylated nucleoside derivatives show antiangiogenic and vascular-
targeted activity, both of these properties may be used for the creation of novel 
effective class of inhibitors and anticancer drugs. [8], [15] 
 
1.5.1.8 Pentose phosphates and the importance of 2-deoxy-L-ribose as 
the inhibitor of tumor metastasis 
 
Pentose phosphates represent the basal structures of ribo- and 
deoxyribonucleotides. Except the oxidative pathway, where the 
D-ribose-5-phosphate (D-Rib-5-P) and 2-deoxy-D-ribose-5-phosphate 
(D-dRib-5-P) are synthesized from glucose-6-phosphate, the pathway through 
the action of nucleoside phosphorylases, as TP, UP or PNP is important for 
their formation. These enzymes are suppliers of the 
2-deoxy-D-ribose-1-phosphate and D-ribose-1-phosphate (D-Rib-1-P). The 
phosphopentomutase transformes D-Rib-1-P into the D-Rib-5-P leading to 
glycolysis. The second possibility is the phosphopentomutase reversible 
conversion of the D-dRib-1-P to D-dRib-5-P and its resulting cleavage into 
glyceraldehyde-3-phosphate and acetaldehyde entering the glycolysis or the 
Krebs cycle. Except their utilization as the energetic sources, their next 
important pathway is to serve for nucleoside and base interconversion. [31] 
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By the action of thymidine phosphorylase the reversible conversion of 
thymidine to thymine proceeds together with release of 
2-deoxy-D-ribose-1-phosphate (D-dRib-1-P). The dephosphorylated product of 
D-dRib-1-P, 2-deoxy-D-ribose (D-dRib) has interesting qualities, it is able to 
stimulate chemotaxis, support tubular formation of endothelial cells (even if this 
ability was formerly ascribed to TP intrinsic action) and give the resistance to 
tumor cells against apoptosis caused by hypoxia. Through the intervention into 
the formation or the blockage of D-dRib effect could be reached the inhibition of 
the tumor growth.  
 
Nakajima et al. [23] put their mind to the possible inhibition of D-dRib by 
2-deoxy-L-ribose (L-dRib), the stereoisomer of D-dRib. In their performed 
studies on the mouse models was shown that L-dRib is very efficient inhibitor 
of angiogenesis and also metastasis of tumor cells overexpressing TP. The 
effectiveness of inhibition of metastasis was higher, compared to tegafur 
(prodrug of 5-FU). By the action of TP, the release and activation of angiogenic 
factors VEGF, IL-8 and matrix metalloproteinase-1 proceeds, hence by the help 
of L-dRib their secretion could be decreased. The last important thing is the 
function of D-dRib as the energetic source in hypoxic tissues, it means in 
tumors also, but L-dRib does not serve as the source of energy, so that its 
administration could cause the lack of energy and restriction of tumor growth. 
 
 
Fig. 27 2-Deoxy-L-ribose (L-dRib), a stereoisomer of D-dRib, can inhibit D-dRib antiapoptotic 
effect and suppress the growth of metastasis. 
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1.5.2 Uridine phosphorylase inhibitors 
 
Preliminary is necessary to refer that most of the compounds able to 
inhibit uridine phosphorylase is not able to be inhibitory active against TP. It is 
assumed that this fact is caused by the presence of larger hydrophobic cavity 
in UP nucleoside-binding site than the TP contains, namely in adjacencies of 
C5 of the base, which is obvious from the structures of efficient inhibitors. The 
most important thing is to preserve the intact C2, N3 and C4 positions of the 
base ring, positions C1 and C5 could be modified in various ways. Cha S. et al. 
[26] mentioned that the 3´-hydroxyl group of nucleosides analogues has to be 
preserved for better exteriorization of inhibitory qualities and that the 
syn-conformation round the N-glycosidic bond is necessary. 
 
 As potent inhibitors of UP were synthesized xylo-, lyxo-, 2,3´-anhydro-2´-
deoxy-, 6,5´-cyclo-, and carbocyclic analogues of uridine, but none of these 
compounds had  the ability to inhibit the uridine phosphorylase. Neither the C5 
substitution brought the incerase of activity against UP. Which basically means 
that these molecules do not bind to the enzyme. As the derivatives which 
proved to be competent for UP inhibition were found acyclouridines and 
2,2´-anhydrouridines as described below. [24] 
 
1.5.2.1 5-substituted acyclouridines 
 
As the most important inhibitors of uridine phosphorylase were 
synthesized specific inhibitors acyclouridine and 5´-substituted analogues of 
acyclouridine (1-(2-hydroxyethoxymethyl)uracils). After the revelation of the 
effect and antiherpetic potencial of acycloguanine (known as acyclovir, showed 
in Fig. 14), other structures resembling to acycloguanine were prepared, where 
the purine was replaced by another base. On the basis of acyclouridine, the 
methyl-, ethyl-, propyl-, isopropyl- or benzyl- derivatives substituted in C5 
position were synthesized (Fig. 28). On the strength of these substitutions it 
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was shown, that the more the hydrophobic chain is long the lower the inhibition 
constant (Ki) is from acyclouridine to the propyl derivative according to the 
theory of hydrophobic region at the active site. But on the other side, the 
isopropyl- and 5,6-tetramethyl- analogues did not decrease but increase the Ki. 
These compounds were tested on the E. coli and on the rat enzyme (UP). 
Different values of Ki show the diversities of the structure of active sites of 
these two enzymes. [25], [26]    
 
 
Fig. 28 Structures of acyclouridines: (1-(2´-hydroxyethoxymethyl)uracils and the structure on the 
right represents hydroxymethyl acyclo compounds 1-(2´-hydroxyethoxy(1´-
hydroxymethyl)methyl)uracils) 
 
In respect to the findings that acyclonucleosides are more potent in the 
inhibition than the non-acyclic compounds, therefore other compunds were 
synthesized by the combination of acyclomoiety and already known 
compounds with proved inhibitory activity 5-benzyluracil (BU) and 
5-m-benzyloxybenzyluracil (BBU). Arised 5-benzylacyclouracil (BAU) is derived 
from BU, the inhibitory activity against UP was enhanced and the increase of 
inhibitory potency showed 5-m-benzyloxybenzylacyclouracil (BBAU), which 
was derived from BBU (Fig. 30). Other compounds like HM-BAU = 
5-m-benzyl-1-(2´-hydroxyethoxy(1´-hydroxymethyl)methyl)uracil and HM-BBAU 
= 5-m-benzyloxybenzyl-1-(2´-hydroxyethoxy(1´-hydroxymethyl)methyl)uracil 
were prepared by the addition of one hydroxymethylene group to the acyclo 
moiety at C3´ position. [9], [26] 
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Fig. 29 5-benzyluracil (BU) and 5-m-benzyloxybenzyluracil (BBU) 
 
Basically, many related compounds were synthesized and it is good to 
mention for example aminomethyl-BBAU, a very potent compound against UP 
studied on mouse liver. Another acyclonucleosides were similarly potent, for 
example aminomethyl-BAU and succinyl derivatives. Findings that the 
2,2´-anhydrouridine and its derivatives are possible inhibitors of UP gave rise to 
synthesis of some combinations of these two groups containing BU or BBU and 
2,2´-anhydrouridine moiety. These analogues obtained a bit higher inhibitory 
activity than the previous acyclonucleosides but simultaneously they were not 
so effective as the best 2,2´-anhydro compound, 2,2´-anhydro-5-ethyluridine. 
 
 
Fig. 30 5-benzylacyclouridine (BAU) and 5-m-benzyloxybenzylacyclouridine (BBAU) 
 
Group of these acyclo nucleosides was further enlarged by 
5-phenylthioacyclouridine (PTAU), 5-phenylselenenylacyclouridine (PSAU) and 
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5-m-benzyloxybenzyl barbituric acid acyclonucleoside (BBBA). In principle, 
BBBA is BBAU with added =O group at C6 position of uracil ring. The assays, 
where the inhibitory activity against E. coli UP and human UP was designated 
have shown that BBAU is stronger inhibitor against both enzymes than BAU. 
PTAU and PSAU have shown stronger activity against human UP than BAU 
but these two compounds were not better inhibitors than BBBA. [9]  
 
Weiming Bu et al. [9] used BAU, BBAU and other compounds for 
determining of interactions of these inhibitors at the active site of UP and in this 
way for better understanding of inhibitory abilities in dependence on the 
structure of inhibitors. The quite large C5 substituent is bonded at the active 
site by an extra additional hydrogen bonds to the enzyme, in contrast to C5 
unsubstituted natural substrates, C5 substituted acyclonucleotides make 
further interactions to Phe162, Phe7 and Tyr163 in hydrophobic pocket. BBAU 
and BBBA containing 5-m-benzyloxybenzyl moiety make next hydrophobic 
interactions to Met234 as well.  
 
The binding of inhibitors differs in two general points in contrast to 
substrate binding as was inscribed in [10], [9] and above in 1.2.1.2 and 1.2.4. 
  
1. The first phenyl ring at the C5 position is close to Phe7 residue 
belonging to the pyrimidine-binding site. The phenyl ring causes 
the displacement of Phe7 and its rotation from original position, 
where Phe7 still undertakes a function in the covering of the 
hydrophobic pocket but now forms additional herringbone 
stacking interactions with the first phenyl ring. 
2. The loop region from residues 225-230 becomes the second 
difference in the inhibitor binding. The loop forms closed 
conformation over the active site in the substrate complex but in 
the inhibitor complex, the loop does not make so fixed enclosure 
and the active site remains partially open. Glu227 is involved in 
establishement of the closed conformation by forming hydrogen 
bonds to other residues, Tyr169 and Asp170, in contrast to 
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inhibitor-enzyme complexes, where Glu227 makes no hydrogen 
bonds with any other residue.  
 
The inhibitors containing benzyloxybenzyl moiety show additional 
differences, Ile228 and Pro229 shift away from the active site to seat the 
second phenyl ring, the side chain Met234 rotates and generates hydrophobic 
interaction with the second phenyl ring.  
 
The acycloribose moiety is so flexible that it could adopt the same 
syn-conformation about the glycosidic bond as sugar ring. This moiety bonds in 
very similar manner as the ribose or 2´-deoxyribose as was shown in [10], 
excepting the fact that acycloribosyl moiety creates only two hydrogen bonds to 
His8 and to water molecule presented in the active site. Which means that the 
acycloribose is held by weaker power in the active site. Interactions C3´ and 
C4´ appear to be more variable, presented is just O5´ interaction. And one 
more exception is BBBA, where only one interaction of O5´ is formed to His8. 
C1´, O2´ and O5´ fill the same positions both at the inhibitors and at the ribosyl 
moiety of nucleosides. [9]   
 
Effect on the fluorinated chemotherapeutics 
 
  The development of UP inhibitors could be useful for the prevention of 
degradation of known chemotherapeutics derived from pyrimidine. Concerning 
the effect of already known inhibitors of UP on the action of fluorinated 
derivatives in anticancer chemotherapy, it is well-known that they potentiate the 
effect through the decrease of degradation in organism. One of very interesting 
molecules is acyclothymidine, the very strong inhibitor of 5´-DFUR 
phosphorolysis. 
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Fig. 31 Acyclothymidine 
 
In the cytotoxicity assays performed for 5-fluoro-2´-deoxyuridine (FdUrd) 
together with BAU or BBAU the incerease of cytotoxicity caused by these two 
compounds was not observed but the restriction of uridine intake into the cells 
proceeds. BBAU also increases the effect of FdUrd on the limitation of tumor 
growth and following reduction in tumor weight. Further, BAU and BBAU are 
able to inhibit the transporting of thymidine and adenosine. Only one-third of 
administered dose is sufficient for reaching the same effect of FdUrd during the 
BBAU administration than when FdUrd is administered alone. [25] [26] 
 
1.5.2.2 Anhydrouridines 
 
2,2´-Anhydrouridines (Fig. 32) were found to be competitive inhibitors of 
the rat and E. coli UP and none of these 2,2´-anhydro compounds was found to 
be inhibitor of E. coli TP. These derivatives are generaly better inhibitors than 
their corresponding acyclo- compounds. According to their measured Ki, it is 
obvious that 2,2´-anhydrouridines are even 33-fold more effective against the 
rat enzyme than the E. coli UP. 2,2´-anhydrouridines are in fixed the high-anti 
conformation, and that is why the distribution of electronic density and the 
properties are different as compared to uridine. [25] 
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Fig. 32 2,2´-Anhydrouridine and 2,2´-anhydro-5-ethyluridine 
 
C5-substitution of 2,2´-anhydrouridines 
 
 These compounds are selective inhibitors of of UP but non-efficient 
inhibitors of TP. C5-substituted 2,2´-anhydrouridines are substrates of neither 
UP nor TP. The addition of the ethyl- group at the C5 position led to the higher 
increase of the inhibitory activity. The resulting 2,2´-anhydro-5-ethyluridine (Fig. 
32) obtained much greater inhibitory activity than both the primary anhydro 
compound and other anhydrouridine derivatives. Next, 5-benzyloxybenzyl 
substituted compounds were more active than those with 5-benzyl C5-
substituted uracil ring. This enhancement of binding of ligands in contrast to 
2,2´-anhydrouridine is in agreement with theory of hydrophobic pocket in UP 
nucleoside binding site, although in the case of anhydrouridines, with the 
longer C5-chain the inhibitory activity does not increase from ethyl- to 
benzyloxybenzyl- moiety but the sequence of effectivity is 2,2´-anhydrouridine 
< 2,2´-anhydro-5-benzyluridine < 2,2´-anhydro-5-(benzyloxybenzyl)uridine < 
2,2´-anhydro-5-ethyluridine. As well as the addition of propyl or isopropyl 
moiety to C5 position led to the decrease of binding with regard to 
2,2´-anhydro-5-ethyluridine. The fixed high-anti conformation may bear ship to 
C5 substituents and their orientation at the active site. The large substituents 
may trouble with access to final conformation, in contrast to previously 
forenamed acyclonucleosides, which are able to rotate round their N-glycosidic 
bond. [25], [24], [33]  
  
Within the scope of tested compounds, when the inhibitory activity was 
found for the mouse enzyme, the activity against human UP was demonstrated 
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also. There exists one exception, 2,5´-anhydrouridine, which shows activity just 
against the mouse enzyme. 
 
The pentose ring and the influence of hydroxyl groups on the inhibitory 
activity 
 
Further investigation was focused on the effect of hydroxy groups at the 
pentose ring. Compounds containing the 5´-hydroxy group show increase of 
inhibition but some derivatives without this group show the inhibitory activity 
also, e.g. 5´-deoxy-5-fluorouridine or 2,5´-anhydrouridine. Generally, from this 
findings emerged the fact that the lack of 5´-hydroxyl group causes the weaker 
binding to the enzyme. In contrast to the previous group, the 3´-hydroxyl group 
is essential for the binding of ß-nucleosides to the enzyme. For example 
2,3´-anhydro-2´-deoxyuridines lack the binding and even if these compounds 
are fixed in the syn-range, this disability to bind appeared in the ß-lyxo- and 
ß-xylouracil (shown in Fig. 33), because these compounds do not possess the 
3´-hydroxyl group in the correct ribo-orientation. The importance of the 
2´-hydroxyl group is not very clear, because the 2,2´-anhydrouridines, which do 
not possess the 2´-hydroxyl group are highly efficient inhibitors of UP and 
contrary to the arabinosyl uracil, which has the 2´-hydroxyl in the 
ara-configuration and figures as the poor UP inhibitor. [24] 
 
.   
Fig. 33 The chemical structures of uridine analogues modified in the pentose moiety, ß-xylouracil 
and ß-lyxouracil. 
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Effect of the conformation around the N-glycosidic bond 
 
According to the N-glycosidic bond and its conformation, four groups of 
uridine derivatives could be described as presented in. [24] 
 
 Derivatives fixed in the syn-range (2,2´-anhydro-, 2,3´-anhydro-2´-
deoxy- and 2,5´-anhydro-) 
 Derivatives fixed in the anti-range (6,5´-cyclo-) 
 Compounds not fixed (ribosyl-, 2´-deoxyribosyl-, 5´-deoxyribosyl-, 
arabinosyl-, xylosyl-, lyxosyl- and acyclo-) 
 Derivatives without N-glycosidic bond (cacbocyclic-) 
 
The best derivatives with demonstrated inhibitory activity were 
2,2´-anhydrouridines followed by acyclonucleosides and ribosides. The inability 
of binding of the carbocyclic compounds (Fig. 34) is due to the lack of 
N-glycosidic bond as in true nucleosides. The 6,5´-cyclonucleosides lost their 
ability to bind also due to their anti-conformation of N-glycosidic bond.  
 
 
Fig. 34 6,5´-Cyclouridine, carbocyclic-2,2´-anhydrouridine and 2,5´-anhydrouridine 
 
As well as the 2,2´-anhydrouridines, the 2,5´-anhydrouridines are fixed in 
the syn-conformation around the N-glycosidic bond and therefore they are 
inhibitory active against UP also.  
 
Uracil nucleosides occupy mainly the anti-conformation and therefore 
they are more rigid in the formation of bounds to the enzyme active site than 
their corresponding acyclonucleosides.  
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All of these facts point to the importance of the N-glycosidic bond in the 
syn-conformation, which is necessary for nucleosides to bind to the enzyme. 
 
Differences between the α- and ß-anomers 
 
On the whole, α-anomers form the weaker bound than their ß-anomers. 
Basically the 5´-hydroxyl group in the α-anomers fills the very similar position in 
the binding site of the enzyme as the 3´-hydroxyl group in the ß-anomers, but 
the 5´-hydroxyl is not able to accomodate the exact or strict position, and that is 
why its binding becomes weaker than in ß-anomers due to the steric blockage, 
which makes the 3´-hydroxyl at the xylo-configuration in the α-xylo and α-lyxo- 
compounds and because of this 3´-hydroxyl group the 5´-hydroxyl is not able to 
bind. This fact was observed for α- and ß-anomers of the 2´-deoxyuridines and 
xylo- and lyxo- compounds. [24] 
 
1.5.3 Novel nucleosides 
 
1.5.3.1 Nucleosides based on 2´-deoxy-2´-fluororibosides 
 
The atom of fluorine substituted for hydroxyl group in the pentosyl moiety 
of nucleosides causes the manifestation of important biological activities. 
Analogues with 2´-deoxy-2´-fluoroarabinosyl moiety show activity against 
herpes simplex, simian varicella, varicella-zoster, human cytomegalo, Epstein-
Barr, hepatitis B viruses. Some of them have also antileukemic activity.  
 
 
Fig. 35 Purine 2´-deoxy-2´-fluoronucleoside 
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2´-deoxy-2´-fluororibosyl moiety containing analogues show also activity 
against some viruses like herpes simplex, pseudorabies, equine abortion, 
influenza or varicella-zoster. 2´-deoxy-2´-fluorouridine (2FUrd, depicted in Fig. 
38) is a substance used for the enzymic transfer of pentosyl moiety for the 
creation of other purine analogues. Transfer of the pentosyl moiety from 2´-
deoxy-2´-fluorouridine to purines involves two coupled reactions using UP or 
TP and PNP as biocatalysts. These new structures (substituted in 2 and 6 
position with amino-, hydrogen-, fluoro-, methyl- or methoxy- group) were 
tested for the antiinfluenza activity. Purine 2´-deoxy-2´-fluroribosides containing 
2-amino substituent on the purine ring appear as more potent against the 
antiinfluenza virus than 2-unsubstituted congeners. 2´-fluoro analogue of 
2´-deoxyguanosine and its counterparts embody the most potent activity. 
Though 2-amino-6-substituted analogues have not shown significant activity, 
they are not useless, because they can be converted by the metabolic 
pathways into other efficient analogues. [19] 
 
1.5.3.2 3´-amino-2´,3´-dideoxyribonucleosides  
 
The next group of interesting nucleosides is made up by 3´-amino-2´,3´-
dideoxyribonucleosides (Table 2) synthesized by Krenitsky et al. [20] by which 
the attractive biological effects were discovered. As the basic structures for the 
syntheses corresponding 2´-deoxyribonucleosides were used.  
 
 
Fig. 36 The basic structure of 3´-amino-2´,3´-dideoxyribonucleosides. 
 
3NH2Thd and 3NH2Urd were synthesized by a quite laborious chemical 
method through the tritylation of the 5´-hydroxy group of ribose moiety followed 
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by the chlorination in 3´-position, then through the deblocking of 5´-hydroxy 
position. Arisen threo-3´-chloro derivatives converted to the erythro-3´-azido 
derivatives and the last step was the subsequent catalytic hydrogenation. 
Synthesis of 3NH2IUrd was performed by the same way as previous 
nucleosides, 3NH2Thd and 3NH2Urd, but under the milder conditions of the 
reactions because of the presence of 5-iodo substituent compared to 
3NH2BrUrd, 3NH2ClUrd and 3NH2FUrd which were synthesized enzymaticaly. 
The procedure used TP (purified from E.coli) as the catalyst. Aminopentosyl 
moiety was transfered from 3NH2Thd to corresponding 5-halogenouracil. 3´-
azido-2´,3´-dideoxyuridine became the starting material for the synthesis of 
3NH2Cyd, it was aminated in the 4-position and subsequently hydrogenated to 
3NH2Cyd.  
 
Name of nucleoside Abbreviation 
Substituents 
R5 R6 
3´-amino-2´,3´-dideoxythymidine 3NH2Thd CH3 OH 
3´-amino-2´,3´-dideoxyuridine 3NH2Urd H OH 
3´-amino-2´,3´-dideoxy-5-iodouridine 3NH2IUrd I OH 
3´-amino-2´,3´-dideoxy-5-bromouridine 3NH2BrUrd Br OH 
3´-amino-2´,3´-dideoxy-5-chlorouridine 3NH2ClUrd Cl OH 
3´-amino-2´,3´-dideoxy-5-fluorouridine 3NH2FUrd F OH 
3´-amino-2´,3´-dideoxycytidine 3´-NH2-dCyd H NH2 
 
Table 2 Pyrimidine 3´-amino-2´,3´-dideoxyribonucleosides, which were synthesized by Krenitsky et 
al. [20] from corresponding 2´-deoxyribonucleosides. 
 
These nucleosides were tested for the ability of inhibition of the growth of 
mammalian cells, bacteria and viruses in vitro. Only 3NH2FUrd was quite 
effective against adenovirus. Tests for the antibacterial activity performed with 
3NH2FUrd  against some Gram-positive bacteria (Staphylococus aureus, 
Streptococcus faecalis and Streptococcus agalactiae) showed the inhibition of 
organisms, whereas the activity against Gram-negative bacteria was not 
demonstrated. The other 3´-amino-2´,3´-dideoxyribonucleosides showed the 
inhibitory activity against neither Gram-positive nor Gram-negative organisms. 
3NH2Cyd  showed cytotoxicity to human sternal marrow cells and to mouse 
connective tissue cells, while 3NH2Thd is also toxic but one-third as 3NH2dCyd. 
Important thing in 3NH2FUrd is that this compound is nontoxic in vivo and have 
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antiviral and antibacterial abilities in concentracions, which do not inhibit the 
growth of mammalian cells. [20] 
 
1.5.4 TP inhibitors and their drawbacks 
 
TP inhibitors and their usage have also some disadvantages, because 
these compounds can inhibit TP directly thereby they can cause the 
accumulation of thymidine in plasm, which cause toxic effect (previously have 
been found that the low TP activity is connected with pathological changes in 
the brain and muscles). Moreover, the TP activity is very important for the 
activation of known antitumor drugs (e.g. 5´-deoxy-5-fluorouridine – 5´-DFUR), 
so the administration of inhibitor together with that drug could cause some 
problems and it is necessary to have respect to this fact. [23] 
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2 Experimental part 
 
2.1 The aims of study 
 
This work largely deals with studies on substrate specifity of the E. coli 
recombinant thymidine phosphorylase (TP) and recombinant uridine 
phosphorylases from E. coli (UP) and two from Salmonella tymiphurium (UP1 
and UP2).  
 
The main goals of this study are: 
 
1. Determination of kinetic parameters for natural substrates 
(thymidine and uridine) for recombinant TP and UP; 
2. Assessment of the role of phosphate anion in the enzymatic 
transformations; 
3. Search for new inhibitors of TP and UP. 
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2.2 Materials and methods 
 
2.2.1 Chemicals 
 
 Uridine phosphorylases (UP, UP1, UP2) - prepared in the Department of 
Biotechnology (Shemyakin-Ovchinnikov Institute of Bioorganic chemistry, 
Russian Academy of Sciences, Moscow, Russia; Head of the 
Department Prof. A. I. Miroshnikov; [Esipov R. S.; Gurevich A. I.; 
Chuvikovsky D. V.; Chupova L. A.; Muravyova T. I.; Miroshnikov A. I.; 
Protein Expr. Purif. 2002, 24, 56-60.]) 
 Thymidine phosphorylase (TP) - prepared in the Department of 
Biotechnology (Shemyakin-Ovchinnikov Institute of Bioorganic chemistry, 
Russian Academy of Sciences, Moscow, Russia) 
 Potassium dihydrogen phosphate (KH2PO4) – Merck, Germany 
 Acetonitrile (MeCN) – Merck, Germany 
 Natrium thiophosphate (Na3PO3S) – Merck, Germany 
 2NH2Urd – 2´-amino-2´-deoxyuridine 
 3NH2Urd – 3´-amino-3´-deoxyuridine 
 2FUrd – 2´-deoxy-2´-fluorouridine 
 3NH2Thd – 3´-amino-3´-deoxythymidine 
 2-O-MeUrd - 2´-O-methyluridine 
 AraFrU – 1-(ß-D-fructofuranosyl)uracil 
 Uridine (Urd) 
 Thymidine (Thd) 
 
2.2.2 Equipment 
 
 Laboratory digital pH-meter Orion, model 420A, US 
 HPLC column – Waters C18; 5 μm; 4,6 x 150 mm 
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 Varian Cary-300 Bio spectrophotometer (software Cary WinUV version 
3.0 (182) – used for determining an enzyme kinetics run and kinetic 
parameters KM and Vmax 
 
2.2.3 Kinetic measurements 
 
The best way to obtain enzyme kinetic data is to use Michaelis-Menten 
equation and Lineweaver-Burk plots. The estimation of KM of phosphorolysis of 
uridine by UPases and of thymidine by TP was obtained by spectrophotometric 
estimation of the reaction rate at 265 nm for TP and 260 nm for UPases where 
the maximum absorbtions were observed. 
 
Reaction conditions: Into the cuvette, the substrate, K-phosphate buffer 
and stock solution of enzyme were added. The enzyme was added for the 
initiation of reaction and than immediately measured. 
 
At first we prepared stock solutions of buffer, substrate and enzymes: 
 
 K-phosphate buffer: 5mM solution (0.68 g was dissolved in 1.0 l), pH = 
7.0 
 The amounts of substrate added into reaction mixture, uridine or 
thymidine, varied from 20 to 60 μl of 100 μM stock solution (0.025 mg in 
1 ml of KPB). 
 Stock solutions of enzymes: 0.95 mg of protein was dissolved in 1.0 ml of 
KPB (5 mM, pH = 7.0) that corresponds to 28.5 U. 20 μl of this stock 
solution is taken into reaction, i.e., 0.57 U of enzyme is taken into 
reaction. 
 
Reaction mixture: Substrate (20, 30, 40, 45, 50, 55 or 60 μl) + 20 μl of 
enzyme + 5 mM KPB in exact amount for refilling to 1.0 ml.  
 
The mixture was mixed and immediately measured. To obtain KM and 
Vmax values, we used the Lineweaver-Burk plots. 
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2.2.4 Substrate specifity 
 
The phosphorolysis of our tested compounds by TP and UP was 
measured by high-performance liquid chromatography (HPLC) analysis. This 
HPLC analysis have been performed in isocratic elution on the reverse phase 
column.  
 
HPLC system: buffer A: 5 mM KPB (pH =  5.5) and buffer B: 0% with one 
exception for AraFrU where the isocratic elution ran in buffer A: 5 mM KPB (pH 
=  5.5) and buffer B: 3%   
 
For single injections on the column were prepared reaction mixtures 
containing tested substrate, enzyme and K-phosphate buffer (KPB) or 
thiophosphate buffer (Na3PO3S) as a solvent. 
 
Stock solution of the substrate was prepared by dissolving of 1.0 mg of 
substrate in 1.0 ml 5 mM KPB. Concentration of enzymes varied for UP from E. 
coli (3.9 mg in 25 ml 5 mM KPB or 7 mg in 1.5 ml 5 mM KPB) stock solutions. 
UP1(2) was used only in concentration 7.2 mg in 1.5 ml 5 mM KPB in stock 
solution. Stock solution of TP contains 3.9 mg in 25 ml 5 mM KPB. 
 
Into the Eppendorf tubes we put 20 μl of substrate stock solution, 20 μl of 
enzyme stock solution and refilled with the 5 mM KPB to 1.0 ml of total volume. 
We prepared KPB solutions with various pH for our reactions. Reaction 
mixtures were performed in pH 6.5, 8.0 or 9.0. The 5 mM thiophosphate buffer 
(all measurements with this buffer were carried out in pH = 8.0) was prepared 
for investigation of the role of phosphate in reactions catalyzed by UP and TP 
and was added into reaction mixtures in the same way as KPB. 
 
Freshly prepared reaction mixtures were injected at HPLC column in 
several time intervals, immediately after the addition of enzyme, after 0.5 hour, 
1.0 hour, 1.5 hour and further injections were dependent on already observed 
activity.  
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HPLC analysis was performed under the conditions of isocratic elution on 
the  UV-based detection was performed at 254 nm. A flow rate was set up to 
1.0 ml/min.  
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3 Results 
 
3.1 Kinetic measurements  
 
Kinetic parameters (Michaelis constant Km, maximum rate Vmax and 
catalytic constant kcat) were assignated for phosphorolysis of uridine by uridine 
phosphorylases and thymidine by thymidine phosphorylase and compared with 
published data. Kinetic parameters are shown in Table 3. All these data have 
been obtained in 5 mM K-phosphate buffer (pH=7.0). We have previously 
shown that the 5 mM buffer has some experimental advantages over the 50 
mM buffer for an enzymatic synthesis of nucleosides.  
 
Substrate/Enzyme KM, µM Vmax, µM min
-1 kcat, sec
-1 
Thymidine/TP 2 95 25 50 
Uridine/UP 3 80 36 77 
Uridine/UP1 73 48 69 
Uridine/UP2 194 74.5 112 
 
Table 3 Kinetic paramerets of enzymatic phosphorolysis of thymidine 
and uridine by the recombinant thymidine phosphorylase (TP, E. coli) and 
uridine phosphorylases from E. coli (UP) and from Salmonella typhimurium 
(UP1 and UP2) 1 
 
1 All the measurements have been performed in 5 mM K-phosphate 
buffer (pH= 7.0) at 23°C. 
 
2 Lit. Data observed for TP by Panova N.G. et al. [14]: KM = 300 µM; Vmax  
= 119 µM min-1; kcat = 198 sec
-1 
 
Under conditions of the present study the phosphorolysis of thymidine by 
TP is reached after one hour a 1:1 equilibrium of thymidine and thymine as it 
followed from the HPLC data of the reaction mixture. Establishment of the 
equilibrium is accompanied by the drop of absorption at 266 nm from 2.24 to 
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2.038 (Δε = 850 M-1cm-1). The molar extinction coefficient for thymidine was 
found to be ε = 9,480 M-1 cm-1. All the measurements have been performed at 
the λ = 265 nm. 
 
3 Lit. Data observed for UP by Panova N.G. et al. [14]: KM = 80 µM; Vmax  
= 180 µM min-1; kcat = 98 sec
-1. 
 
In all the experiments with UPases, practically complete phosphorolysis 
was observed after 1 h and the Δε value was determined to be 1,840 M-1cm-1. 
During the phosphorolysis, displacement of the maximum absorption from 261 
to 259 nm was observed; all the measurements have been performed at the 
λ = 260 nm. 
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Lineweaver-Burk Plot of Uridine Phosphorolysis by 
S. tymiphurium Uridine Phosphorylase 1
0
0,01
0,02
0,03
0,04
0 0,002 0,004 0,006 0,008 0,01
1/c
1
/V
 
Graph 1 shows the behaviour of uridine phosphorolysis, 1/c [μM-1], 1/V [min. μM-1]. 
 
K M = 73 μM 
Vmax = 48 μM min
-1 
kcat = 69 sec
-1 
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Lineweaver-Burk Plot of Uridine Phosphorolysis by 
S. tymiphurium Uridine Phosphorylase 2
0
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0,04
0,05
0 0,005 0,01 0,015
1/c
1
/V
 
Graph 2 shows the behaviour of uridine phosphorolysis by UP2, 1/c [μM-1], 1/V [min. μM-1]. 
 
K M = 194 μM 
Vmax = 74.5 μM min
-1 
kcat = 112 sec
-1 
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Lineweaver-Burk Plot of Uridine Phosphorolysis by 
E. coli Uridine Phosphorylase 
0
0,02
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0 0,005 0,01 0,015 0,02
1/c
1
/V
 
Graph 3 shows the behaviour of uridine phosphorolysis by UP, 1/c [μM-1], 1/V [min. μM-1]. 
 
K M = 80 μM 
Vmax = 36 μM min
-1 
kcat = 77 sec
-1 
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Lineweaver-Burk Plot of Thymidine Phosphorolysis 
by E. coli Thymidine Phosphorylase
0
0,05
0,1
0,15
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0 0,01 0,02 0,03 0,04
1/c
1
/V
 
Graph 4 shows the behaviour of thymidine phosphorolysis, 1/c [μM-1], 1/V [min. μM-1]. 
 
K M = 95 μM 
Vmax = 25 μM min
-1 
kcat = 50 sec
-1 
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3.2 Experiments with UP 
 
In the following part of our work, we illustrate the substrate specifity of 
investigated enzymes. We have compared the similarity of UP from 
Escherichia coli  (UP) and Salmonella typhimurium (UP1 and UP2). 
 
3.2.1.1 Studies on 2´-O-Methyluridine and 1-(ß-D-fructofuranosyl)uracil 
 
2´-O-Methyluridine (2´-O-MeUrd) and 1-(ß-D-fructofuranosyl)uracil 
(AraFrU) devoid of both substrate and inhibitory activities for our tested uridine 
phosphorylases from E. coli and S. typhimurium. The activity was tested at pH 
= 6.5, 8.0 and 9.0 with 5 mM KPB. The thiophosphate buffer was not used for 
these two compounds.  
 
 
Fig. 37 No substrate ativityfor uridine phosphorylases for E. coli and S. typhimurium was found in 
our measurements for AraFrU and 2-O-MeUrd. 
 
But these two compounds were not found to have some effect on the 
activity of enzymes as is shown below in Table 4 and in Table 5.  
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2´-O-Methyluridine (2´-O-MeUrd) 
enzyme pH 
Retention 
time (Rt, min) 
reaction time 
product 
% 
UP 6,5 7,72 30 min − 
         
UP 8,0 7,84 20 (50) hours − 
        
UP2 8,0 9,96 22 hours − 
         
UP 9,0 10,42 (10,19) 17 (40) hours − 
         
Table 4 
 
 
 
 
 
 
UP - Recombinant Uridine Phosphorylase from E. coli 
 (stock solution = 7 mg in 1,5ml KPB) 
UP2 - Recombinant Uridine Phosphorylase from S. typhimurium 
 (stock solution = 7,2 mg in 1,5ml KPB) 
For the reaction was used volume 20 μl of the stock solution of enzyme, 
i.e., 0.57 U of enzyme is taken into reaction mixture. 
HPLC system: 
 all reactions for 2´-O-MeUrd have been preformed in isocratic 
elution B 0%, buffer A: 5 mM KPB (pH 5.5) 
 the system for AraFrU was as follows: buffer A: 5 mM KPB (pH 
5,5); buffer B: 5 mM KPB in 60% MeCN (pH 5,5); isocratic B 3% 
 
3.2.1.2 Studies on 2´-deoxy-2´-fluorouridine 
 
Reaction mixtures with 2´-deoxy-2´-fluorouridine were prepared for 
both types of buffer (5 mM KPB and Na3PO3S) and also here the third type of 
buffer was used (50 mM Na3PO3S). The pH values were 6.5, 8.0 and 9.0. 
Apparently, 2FUrd was phosphorylated only in Na3PO3S in pH = 8.0 but in very 
low yield, the other values of pH were not found to be suitable for reaction 
1-(ß-D-fructofuranosyl)uracil (AraFrU) 
enzyme pH 
Retention 
time (Rt, min) 
reaction time 
product 
% 
UP 6,5 2,25 30 min -  
Table 5 
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process. After the analysis of reaction mixtures containing 20 μl of enzyme 
solution, where the yield of product was very poor, we prepared and measured 
the process of phosphorolysis with higher amount of enzyme stock solution 
(80 μl). Reaction mixtures prepared in this manner did not cause the increase of 
yielded product but the reaction proceeded faster. Table 6 represents our 
obtained results.  
 
2´-Deoxy-2´-fluorouridine (2FUrd) 
enzyme/volume buffer pH 
Retention 
time (Rt, 
min) 
reaction 
time 
product 
% 
UP (20μl) 
KPB 
5 mM 
6,5 7,86 50 hours − 
         
UP (20μl) 8,0 7,93 50 hours − 
         
UP (20μl) 9,0 7,87 17 hours − 
         
UP (20μl) 9,0 7,82 40 hours − 
         
UP2 (20μl) 8,0 7,49 21 hours 0,60% 
         
UP (20μl) 
Na3PO3S 
5 mM 
8,0 7,86 24 hours 0,57% 
         
UP2 (20μl) 8,0 7,86 24 hours 0,44% 
         
UP (80μl) 8,0 7,90 1,5 hour 0,51% 
         
UP2 (80μl) 8,0 7,95 1,5 hour 0,39% 
         
UP (80μl) 
Na3PO3S 
50 mM 
8,0 7,89 2,5 hours 0,57% 
         
UP2 (80μl) 8,0 7,90 2,5 hours 0,44% 
         
Table 6 
 
UP - Recombinant Uridine Phosphorylase from E. coli 
 (stock solution = 7 mg in 1,5 ml KPB) 
UP2 - Recombinant Uridine Phosphorylase from S. typhimurium 
 (stock solution = 7,2 mg in 1,5 ml KPB) 
HPLC system: all the reactions have been performed in isocratic elution 
B 0%, buffer A: 5 mM KPB (pH 5.5) 
Injected volumes of reaction mixtures were 20 μl and 80 μl respectively. 
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Fig. 38 2´-deoxy-2´-fluorouridine (2FUrd) 
 
3.2.1.3  Results for aminouridines 
 
Our work was focused on two uridine derivatives, 2´-amino-2´-
deoxyuridine (2NH2Urd) and 3´-amino-3´-deoxyuridine (3NH2Urd). 
 
 
 
As is obvious from our obtained data, 2NH2Urd is a quite good substrate 
for phosphorolysis made by both UP from E. coli and UP2 from S. 
thyphimurium in pH = 8.0. Results obtained for 2NH2Urd are shown below in 
Table 7.  
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 2´-Amino-2´-deoxyuridine (2NH2Urd) 
enzyme buffer pH 
Retention time 
(Rt, min) 
reaction 
time 
product 
% 
UP 
KPB 
5 mM 
6,5 3,36 30min − 
       
UP2 8,0 3,50 22 hours 60,40% 
        
UP 8,0 3,44 1 hour 20,40% 
    20 hours 86,00% 
UP 
Na3PO3S 
5 mM 
8,0 3,36 1,5 hour 66,20% 
    20 hours 81,60% 
UP2 8,0 3,39 1,5 hour 65,00% 
    20 hours 68,20% 
Table 7 
 
Injected volumes of reaction mixtures in column were 20 μl.  
UP - Recombinant Uridine Phosphorylase from E. coli 
 (7 mg in 1,5 ml KPB) 
UP2 - Recombinant Uridine Phosphorylase from S. typhimurium 
 (7,2 mg in 1,5 ml KPB) 
HPLC system: all the reactions have been performed in isocratic elution 
B 0%, buffer A: 5 mM KPB (pH = 5.5) 
 
3´-Amino-3´-deoxyuridine (3NH2Urd) 
enzyme buffer pH 
Retention 
time (Rt, 
min) 
reaction 
time 
product 
% 
UP (20μl) 
  
KPB 
5 mM 
  
  
  
8,0 3,16 20 hours 9,80% 
     
UP2 (20μl) 8,0 3,08 3,5 hour 4,50% 
     20 hours 23,90% 
UP2 (80μl) 8,0 3,04 22 hours 23,00% 
         
UP (80μl) 8,0 3,08 22 hours 36,60% 
         
UP (20μl) 
Na3PO3S 
5 mM 
  
  
8,0 3,10 3 hours -  
         
UP2 (20μl) 8,0 3,05 3 hours -  
         
Table 8 
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UP - Recombinant Uridine Phosphorylase from E. coli 
 (stock solution = 7 mg in 1,5 ml KPB) 
UP2 - Recombinant Uridine Phosphorylase from S. typhimurium 
 (stock solution = 7,2 mg in 1,5 ml KPB) 
HPLC system: all the reactions have been performed in isocratic elution 
B 0%, buffer A: 5 mM KPB (pH = 5.5) 
 
In the case of 3NH2Urd, indeed, the reaction proceeded but slowly and 
with quite low final yield (Table 8). 
 
3.3 Experiments with TP 
 
3.3.1.1 Phosphorolysis of 3´-amino-3´-deoxythymidine 
 
Substrate specifity of thymidine phosphorylase from E. coli was studied 
in the case of 3´-amino-3´-deoxythymidine (3NH2Thd) at pH = 6.5 or 8.0 in 
prepared reaction mixtures. Table 9 presents our results achieved by HPLC 
analysis. 
 
 
3´-Amino-3´-deoxythymidine (3NH2Thd) 
enzyme buffer pH 
Retention 
time (Rt, 
min) 
reaction 
time 
product 
% 
TP  6,5 4,02 20 hours 25,50% 
 KPB         
TP 5 mM 8,0 4,02 45 min 13,60% 
       
Table 9 
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TP – thymidine phosphorylase from E. coli 
HPLC system: all the reactions have been performed in isocratic elution 
B 0%, buffer A: 5 mM KPB (pH = 5.5) 
 
3.3.1.2 The role of pH and phosphate 
 
In to gain further insight into the substrate activity of aminodeoxy 
nucleosides, we have investigated two aspects of this reaction, 1 – the role of 
the pH of the medium, and 2 – the role of the phosphate. 
 
1. pH – we have performed our measurements at three different 
values of pH, 6.5, 8.0 and 9.0.  
2. Buffer – two types of buffers were involved in our measurements, 
5 mM K-phosphate buffer (for reactions at all kinds of pH values) 
and 5 mM thiophosphate buffer (only for measurements at pH = 
8.0) 
All obtained data are depicted above in Table 5-10. 
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4 Discussion 
 
Determination of kinetic constants 
We have measured kinetic parameters in 5 mM KPB, pH = 7.0. In the 
most publications the 50 mM buffer was employed in kinetic studies by other 
authors leading to somewhat different results as is shown above. 50 mM K-
phosphate buffer, pH = 7.5 for UP and pH = 6.5 for TP, was used for 
determination of kinetic parameters by Panova et al. [14]. Zinchenko et al. [34] 
used 50 mM KPB at pH = 7.0. 
 
2-O-MeUrd and AraFrU 
No formation of nucleobases was observed either in variations of pH or 
after quite long incubation time (even 50 hours). That data clearly show that the 
bulky substituent at the C2´ and C1´ carbon atoms, respectively, preclude the 
formation of productive enzyme-analog complex and proceeding of 
phosphorolysis. 
 
2FUrd 
2´-Deoxy-2´-fluorouridine displayed very low substrate activity for TP and 
UPases, which is in accord with reported data on the synthesis of purine 2´-
deoxy-2´-fluoro-ß-D-ribonucleosides using 2´-deoxy-2´-fluorouridine as a donor 
of the pentofuranose residue in the enzymatic transglycosylation reaction. 
(Tuttle J. V. et al. [19], Zaitseva G. V. et al. [36])  
 
The very low substrate activity of 2´-deoxy-2´-fluorouridine for both 
enzymes may be explained by higher electronegativity of C2´ fluorine atom and 
by the shortening and strengthening of glycosidic bond upon replacement of the 
2´-hydroxyl group of uridine by a fluorine atom. This glycosidic bond is hard to 
cleave for enzymes. 
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2NH2Urd and 3NH2Urd 
 
As is clearly visible from our findings, reactions proceeded only in 
pH = 8.0 and is much faster in the presence of Na3PO3S than in KPB under the 
same conditions, but finally the phosphorolysis stopped at the same yield – the 
reaction got into an equilibrium faster.  
 
It was previously shown in experiments with UP and TP within the whole 
E. coli cells (50 mM K-phosphate buffer, pH=7.0) that substrate activities of 2´-
deoxyuridine, 3´-deoxyuridine, 2´-amino-2´-deoxyuridine and 3´-amino-3´-
deoxyuridine are 35.5%, 6.4%, 11.6% and 0.6% compared to uridine, activity of 
which was calculated as 100%. From these data it remained unclear the 
reason for an activity drop by going from uridine to 2´-deoxyuridine and further 
2´-amino-2´-deoxyuridine, and, moreover, very low activity of 3´-amino-3´-
deoxyuridine vs 3´-deoxyuridine. [34]  
 
The intact cells of Erwinia herbicola AJ 2803 have been employed by the 
Japanese workers as a biocatalyst for the synthesis of 2´-amino-2´-
deoxyinosine using chemically prepared 2´-amino-2´-deoxyuridine as a donor of 
the pentofuranose moiety and hypoxanthine (3.23:1.0 ratio, mol) as an acceptor 
in 34% isolated yield based on the acceptor. [38] Recently, the results of studies  
have been reviewed by Utagawa [39]. 
 
3NH2Thd 
Our measurements showed that TP is able to phosphorylased 3NH2Thd 
but in not very good portion of product. After measurements with TP we tried to 
test this compound in reactions with UP from E. coli and UP1 and UP2 from 
S. typhimurium. 3NH2Urd devoid of activity for both types of enzyme. 
 
It was also shown that 3´-amino-3´-deoxythymidine is a very poor 
substrate of TP from E. coli. Krenitsky et al. [20] have used this 3NH2Thd as 
donor of carbohydrate moiety in the reaction of enzymic transglycosylation. 
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Later, 3´-amino-3´-deoxythymidine was used by Zaitseva G. V. et al. [37] 
as a donor of the pentofuranose moiety in the transglycosylation of adenine and 
guanine and it was found that it is poor substrate also. 
 
The role of pH and thiophosphate buffer 
It was found that pH plays very important role, viz., at pH = 6.5 the 
enzymatic phosphorolysis proceeds extremely slowly, whereas at pH = 8.0 the 
reaction is going with reasonable rate (which is apparent for 3NH2Urd and 
2NH2Urd). 
 
Inorganic phosphate is an essential co-factor to complete the reaction. In 
pH = 6.5 we supposed that the amino group in 3NH2Urd and 2NH2Urd exists in 
–NH3
+ form and makes a strong ionic bond with -PO4
3-, but our results are 
different. In 3NH2Urd in Na3PO3S there was no reaction observed. Because we 
can suppose that –PO3S
3- makes stronger bond (ionic) than –PO4
3- and 
therefore there is no reaction. In pH = 8.0 the amino group exist as –NH2. It 
makes hydrogen bond, which is weaker than the ionic bond for binding -PO4
3- 
and –O- can have influence to C1´ of ribose moiety (to glycosidic bond). 
Probably because of that the reaction of 3NH2Urd proceeded in KPB but in 
thiophosphate buffer not.  
 
The amino group in C2´ of ribose is stereospecific for reaction. The 
reaction of 2NH2Urd in Na3PO3S buffer proceeds much more faster than in 
KPB but after 20 hours the reaction was on the same level as reaction in KPB 
(round 80%). The acceleration of reaction rate in Na3PO3S buffer is the result 
of forming stronger hydrogen bond between –O- of the buffer and –NH2 of the 
ribose (hydrogen bond is a presumption for the effectiveness of 
phosphorolysis). Lower pH values cause the formation of ionic bonds and the 
reaction can not proceed. 
 
To understand the role of phosphate, we investigated the reaction in 
5 mM thiophosphate buffer taking into account that thiophosphoric acid is more 
acidic as phosphoric, on the one hand, and sulphur atom is more nucleophilic 
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than oxygen. [35], [30] However, we have not observed essential differencies in 
the reaction rate in both buffers. 
 
We have not found some efficient inhibitor, all of our tested compounds 
were either substrate or had no influence on the enzyme function. We added 
the natural substrate (Urd or Thd) into reaction mixture containing modified 
nucleoside and enzyme and we monitored if the enzyme is able to do the 
phosphorolysis of natural substrate in the presence of modified nucleoside. By 
all of tested compounds the enzyme was not able to react. 
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5 Conclusions 
 
The most important feature of ivestigated enzymes consists in high 
sensibility to structural changes of substituents at secondary carbon atoms of 
the pentofuranose ring. 
 
The important observation is that aminodeoxy nucleosides studied by us 
showed that they are not substrates in the ammonium form of TP and UPases, 
whereas display satisfactory substrate activity in the amino form. Whereout we 
can designate the importance of pH in our performed reactions for the activity 
of enzymes. 
 
The most important conclusion of this study consists in gaining further 
insight into the mechanism of functioning TP and UP that is very important in 
design of preparative synthesis of nucleosides using these enzymes as 
biocatalysts. 
 
The detailed understanding of TP and UPs functions could be 
instrumental in syntheses and development of new inhibitors of these enzymes 
and in following research or development of new potencial anticancer 
chemotherapeutics.  
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